

Cumulative Index

VOLUMES 4-6

JANUARY, 1967-NOVEMBER, 1969



Cumulative Index

- Abdominal pain
in hereditary hemorrhagic disease,
5:56-57
postoperative, 5:1155-1156, 1174-
1175, 1177
regional-block therapy for, 5:1182
- Abortion
defibrination and, 5:417-418
water and electrolyte disturbances
in, 5:721-723, 725-726
- Abruptio placentae, defibrination and,
5:401-411
- Acetaminophen in treatment of pain,
5:1106-1107
- Acetazolamide
dosage and preparation of, 6:1228
epilepsy and, 6:1224
side-effects of, 6:1226-1227
- Achilles tendon reflex, thyroid hormone
and, 6:461
- Achondroplasia, 5:237
- Acid-base balance
description of, 5:635-639
in poisoning, 4:609, 649-652, 656-
657, 676
in surgical patients, 5:709-713
See also Acidosis; Alkalosis
- Acidosis
azotemia with, 5:632-634
in burn patients, 4:1204, 1219-1220
correction of, 4:1220-1221
causes of, 5:641-642
diabetic, *see* Diabetic ketoacidosis
in infants, 5:690-692
metabolic, 5:642-653; 6:320-321
causes, 5:643
correction, 4:516-517, 518; 5:647-
653
in shock, 4:295
in surgical patients, 5:710-711
treatment, 5:647-653
in renal failure, 6:1039
renal tubular, 4:515-521
respiratory, 5:653-655; 6:34-35, 82,
261-270, 276, 317, 320, 350
in emphysema, 6:269-270, 337,
339-340
I.P.P.B. in, 6:98-102
pCO₂ and, 6:243
in surgical patients, 5:711-713
therapy for, 6:269-270, 347, 354-
356
- Aciduria, hereditary orotic, 4:1037
- Acoustic neuroma (neurinoma), vertigo
and, 6:576-579, 613
- Acrocyanosis, 4:382
- Actinomycosis, 6:1124-1126
- Activated charcoal therapy for neu-
ropathy, 5:1246
- Addison's disease, 5:179-183
morphine dosage with, 5:1141
- Adenomas
islet-cell, 4:1001
thyroid, 6:535
- Adipose tissue, 4:1083-1088
lipid mobilization from, 4:1087-1090
metabolism of, and obesity, 4:1083-
1094
reduction of heat loss and, 4:1149
- ADL (activities of daily living) test,
5:896
of stroke patients, 5:978, 980-981
- Adolescence
changes of health in, 6:648-649
delayed, 5:226-228
hemophilia in, 5:121-123
psychotropic drug hazards in, 6:795
testicular androgen deficiency in,
5:189-195
- Adrenal cortex, diseases of
affecting growth, 5:168-183
potassium excess from 5:668
- Adrenal corticosteroids
in blood platelet disorders, 5:423
as nonspecific anti-inflammatory
agents, 5:780
in obstructive pulmonary disease,
6:303-305, 356
psychotic reactions from, 6:740
purpura from, 5:454

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1364 / Cumulative Index

- relative anti-inflammatory potency of, 5:874
- in treatment of allergy, 5:843-851
 - in atopic dermatitis, 5:869-870, 871, 873-875
 - in drug reactions, 5:811
 - in emergencies, 5:788-789, 844
 - in gastrointestinal allergy, 5:863
 - hazards and complications, 5:838, 848-850
 - side effects, 5:843, 847-848
 - in urticaria, 5:833, 844
- See also* Corticosteroid therapy; Steroid therapy
- Adrenal hyperplasia, congenital, 5:168-174
- Adrenal steroid therapy in idiopathic chronic insulin resistance, 4:19-21
- Adrenocorticotrophic hormone therapy for Bell's palsy, 5:1281-1282
- for postinfectious neuropathy, 5:1264
- Aerosol therapy in bronchopulmonary disease, 6:361-370
- Afibrinogenemia, congenital surgical care in, 5:78-79
- therapy for, 5:51-52
- Agranulocytosis as drug side-effect, 5:1108, 1118, 1273
- Airway and respirator care of neuropathic patient, 5:1214
- in postinfectious neuropathy, 5:1265
- Airway obstruction
 - aerosol therapy, 6:361-370
 - cor pulmonale in, 6:248-260
 - definition of, 6:12, 233
 - hypoventilation and, 6:83
 - management of secretions, 6:297-300, 353-354
 - recognition of, 6:47
 - reduction of, in obese, 4:1173-1175
 - respiratory acidosis and, 6:98
 - tests for, 6:233-247
 - therapy for infectious, 6:322-324, 354
 - tracheal intubation and tracheotomy in, 6:47-60
- Akinetic seizures, 6:1220
- Albinism, bleeding in, 5:448
- Albright's Sebright-Banton syndrome, 5:230-237
- Albuminuria as reaction to salicylates, 5:1103
- Alcoholic cirrhosis, *see* Cirrhosis—alcoholic
- Alcoholic neuropathy, 5:1249-1262
- complications of, 5:1254
- convalescent and long-term care of, 5:1260
- prognosis for, 5:1260-1261
- protection of patient with, 5:1213
- therapy for
 - auxiliary therapeutic measures, 5:1259-1260
 - basis and scope of therapy, 5:1249-1250
 - specific therapeutic measures, 5:1250-1259
- Alcoholics Anonymous, 6:764, 768, 770-773
- Alcoholism, 6:760-766
 - diagnosis of, 6:760-762
 - hand in, 6:665-666
 - magnesium deficiency with, 5:671
 - menopausal osteoporosis and, 5:577
 - sociopathy compared to, 6:708-709
 - treatment of, 6:762-775
 - clergyman's role, 6:890-891
 - drugs, 6:774-775
 - family therapy, 6:772-773
 - group therapy, 6:768-772
 - relapse, 6:765-768
 - resistance to treatment, 6:763-764
 - withdrawal in, 6:740-742
- Aldosteronism
 - magnesium deficiency with, 5:671
 - potassium deficiency with, 5:665
- Alkalis in poisoning, 4:729-733
- Alkaloids in Parkinson's disease, 5:284, 293, 295
- Alkalosis
 - causes of, 5:642
 - metabolic, 5:655-660; 6:320
 - in surgical patient, 5:710
 - treatment, 5:658-660
 - respiratory, 5:660-661; 6:271-276, 320
- Allergic emergencies, 5:775, 782-791
 - antihistamines in, 5:789, 842
 - corticosteroids in, 5:788-789, 844
 - in food allergy, 5:859-860
- Allergic reactions
 - to analgesics, 5:1103, 1112, 1115, 1118
 - definition of, 5:777
 - types of, 5:777-781
 - anaphylactic, *see* Anaphylaxis
- Allopurinol for uric acid stones, 4:532-536
- Alpha-acid glucosidase deficiency, 4:1002
- Alpha-adrenergic blocking agent, 4:247-248, 374, 380-381
- Alpha-beta concept, 4:247-248
- Alphaprodine, 5:1144, 1145

- for labor pain, 5:1144, 1145
- for postoperative pain, 5:1160, 1176
- Aluminum salicylates in treatment of pain, 5:1099, 1101
- Alveolar-capillary block syndrome, treatment in, 6:103-117
- Alveolar hypoventilation, *see* Alkalosis—respiratory
- Alveolar proteinosis, treatment of, 6:109
- Amebiasis
 - hepatic, 6:153-155
 - with pericarditis, 4:150-151
- American Diabetes Association, food exchange system of, 4:1132-1134
- Amino acid metabolism, disorders of, 4:1030-1031
 - mental retardation and, 4:1019-1029
- Aminopyrine therapy for pain, 5:1108
- Ammonia
 - intoxication from, and congenital lysine intolerance, 4:1030-1031
 - in poisoning, 4:638
- Amniotic fluid embolism and defibrination, 5:415-417
- Amphetamine therapy
 - in obesity, 4:1138-1141
 - for pain, 5:1116, 1118, 1119, 1124
 - in Parkinson's disease, 5:293, 297
- Amphetamines, 6:803-804
 - users of, 6:714-715
- Amphotericin B therapy
 - anemia from, 4:953
 - in cryptococcus meningitis, 4:956-958
 - for histoplasma pericarditis, 4:149-150
 - in mycotic meningitis, 4:951, 952, 959
 - renal failure from, 4:953
 - in systemic fungal infections, 4:951-959
- Amputations
 - lower-extremity, 4:416-441
 - bilateral, 4:434-435
 - gait training in, 4:433-435
 - above knee, 4:420-421
 - below knee, 4:419-420
 - optimum level of, 4:418-421
 - postoperative measures, 4:421-425
 - preoperative measures, 4:416-418
 - prosthesis, 4:421-425, 427-433, 439-440
 - reasons for, 5:1047, 1048
 - rehabilitation after, 5:1047-1055
 - sites of, 5:1048-1049
- Amyloidosis, 5:1233-1234
 - following immunization, 5:881
- Amyotrophic lateral sclerosis, 5:1003
- Amyotrophy, 5:1229
- Anal pain, therapy for, 5:1185
- Analgesic therapy
 - antipyretic and anti-inflammatory combined antipyretics and narcotics, 5:1117-1118
 - varieties, 5:1095-1110
 - combinations and mixtures of, 5:1116-1119
 - drug interactions, 5:1162
 - drug tolerance and, 5:1129
 - side effects, 5:1118-1119
 - mild, 5:1094-1120
 - classification by drug activity, 5:1095-1116
 - criteria for drug use, 5:1094-1095
 - non-narcotics, 5:1110-1114
 - for neuropathy, 5:1235, 1239, 1250, 1266
 - for obstetric and gynecologic patients, 5:1164-1179
 - alaphrodine, 5:1145, 1171
 - labor pain, 5:1165-1171
 - meperidine, 5:1144, 1171
 - postoperative pain in gynecologic patients, 5:1174-1177
 - postpartum pain, 5:1172-1174
 - for postoperative pain, 5:1156
 - choice of drug, 5:1160, 1162
 - drug administration, 5:1154-1155, 1158, 1159
 - of gynecologic patients, 5:1174-1177
 - side-effects, 5:1157
 - potent drug forms for, 5:1136-1150
 - regional anesthetic, 5:1181
 - See also* Narcotic analgesic therapy; specific analgesics
- Anaphylaxis, 5:775, 782-791
 - clinical manifestations of, 5:782-783
 - as drug reaction, 5:1103, 1112

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
 Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
 Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1366 / Cumulative Index

- etiology of, 5:786-787
- fundamental mechanism of, 5:778, 783
- from immunization, 5:881-882
- prophylaxis against, 5:789-790
- treatment of, 5:787-789
 - antihistamines contraindicated, 5:839, 840
 - corticosteroids, 5:788-789, 844, 845
- Androgen therapy for menopause, 5:552-554, 558-559
 - osteoporosis treatment, 5:553-554
- Anemia, 4:671
 - after amphotericin B therapy, 4:953
 - aplastic, 5:1108, 1273
 - thrombocytopenia with, 5:435-436
 - hemolytic, drug-induced, 5:1105-1106
 - iron-deficiency, 5:1102
 - pernicious, mental retardation and, 4:1038-1039
 - in pyrogenic meningitis, 4:902
 - pyridoxine-responsive, 5:1258
 - of renal failure, 6:1028-1029, 1036-1038
- Anesthesia
 - conduction, labor pain and, 5:1168
 - timing for conduction anesthesia, 5:1171
 - postoperative pain and, 5:1155, 1157, 1158-1159
 - regional (local), *see* Regional-block therapy
- Aneurysm, false, 4:409
- Angina pectoris, pain with, 5:1085, 1087, 1089
- Angioneurotic edema
 - as drug reaction, 5:1103, 1112
 - hereditary, 5:830
- Angiosarcoma, treatment of, 6:418-419
- Anhidrosis and diabetes, 4:58-59
- Anileridine therapy, 5:1144, 1145
- Aniline derivative therapy, 5:1104-1107
 - side-effects of, 5:1105-1107, 1118
- Ankylosing spondylitis, 5:1011
 - rehabilitation in, 5:1015-1016
 - respiratory failure with 6:39
- Anniversaries and changes in health, 6:650
- Anorexiants drugs in obesity, 4:1138-1142
- Anterior root intrathecal phenol block therapy, 5:1183
- Anterolateral cordotomy, pain relief
 - from
 - of cervical region, 5:1201
 - thoracic, 5:1200
- Antibiotic therapy
 - for brain swelling, 4:968
 - for diabetic patients, 4:115-116
 - in gangrene, diabetic, 4:104-105
 - in meningococcal meningitis, 4:934-936
 - in neonatal meningitis, 4:911-914
 - in neurogenic vesical dysfunction, 4:53
 - in oral ulcerations, 4:558-559, 567-569
 - in poisoning, 4:605
 - in postpericardiotomy syndrome, 4:174
 - in purulent pericarditis, 4:139-141
 - in pyogenic meningitis, 4:900, 902-906, 920-926
 - in tuberculosis meningitis, 4:939-942
 - in tuberculosis pericarditis, 4:183-187
 - in urinary infections, 4:507-510
 - in viral meningitis, 4:96
- Anticholinergic drugs
 - in gastrointestinal allergy, 5:862-863
 - in Parkinson's disease, 5:285-294, 318
- Anticoagulant therapy
 - in arterial disorders, 4:358-361
 - in arteriosclerosis obliterans, 4:96
 - in coronary artery disease (diabetic), 4:99
 - in diabetes, 4:95, 115
 - in pericarditis of acute myocardial infarction, 4:177
 - in postinfarction syndrome, 4:179
- Anticoagulants, circulating, 5:26-27, 58-59
- Antidotes for poisoning, 4:605, 616-624
- Antihistaminic drugs, 5:780
 - in Parkinson's disease, 5:285-286, 293, 296
 - in treatment of allergy, 5:837-843, 850
 - in atopic dermatitis, 5:875
 - in drug reactions, 5:811
 - in emergencies, 5:789, 842
 - in gastrointestinal allergy, 5:862
 - in urticaria, 5:831-833, 834, 835, 838, 841
 - types of, 5:840-842
- Antipyrene therapy for pain, 5:1108
- Aortography, 4:395, 397
- Aortoiliac arteriosclerosis, surgery for, 4:386-389
- A.P.C. (aspirin, phenacetin, caffeine) therapy for pain, 5:1114, 1116, 1118
 - side-effects of, 5:1119
- Aphasia
 - childhood, 4:797-799

- diagnosis of, 6:875-877
- Apresoline-induced neuropathy, 5:1239
- Aphthae, recurrent (aphthous stomatitis, recurrent), 4:558-559
- Arboviruses, 6:1146-1147
- Arrhythmia, 6:1193
- Arm pain
- neuropathic, 5:1215-1221
 - regional-block therapy for, 5:1185
- Arsenic neuropathy, 5:1240-1242
- Arteriography
- air studies in epilepsy and, 6:1212-1212
 - peripheral, in diabetic atherosclerosis, 4:114
- Arteriosclerosis, occlusive
- anticoagulant therapy for, 4:358-361
 - aortoiliac, 4:386-399
 - care of extremities in, 4:354-357
 - femoral, 4:386-394, 399-400
 - ischemic neuropathy with, 5:1267
 - physical activity with, 4:351-353, 361-362
 - surgery for
 - aortoiliac, 4:394, 397-399
 - complications, 4:401-403
 - contraindications, 4:394
 - femoral artery, 4:399-400
 - indications, 4:386-393 - with tropic changes
 - demarcation of lesion, 4:361-362
 - healing, 4:366-367
 - increase in circulation, 4:362-365
 - physical activity, 4:361-362
 - preventing spread, 4:365
- Arteriosclerosis, renal, in diabetic nephropathy, 4:142
- Arteriosclerosis obliterans
- anticoagulant therapy for, 4:358-359
 - care of extremities in, 4:354-357
 - diabetes and, 4:95-96, 103
 - intermittent claudication in, 4:352-353, 376-377
 - ischemic neuritis in, 4:358
 - smoking with, 4:358
 - surgery for, 4:386-387
 - vasodilator drugs for, 4:376-378
- Arteriosclerotic heart disease
- weight reduction in, 4:1143-1144
- See also* Coronary heart disease
- Arthritis
- analgesic therapy for, 5:1095
 - antibiotics in, 6:1071-1080, 1087-1089, 1095-1097
 - for children, 6:1104-1109
 - gonococcal arthritis, 6:1135-1137
 - in children, 6:1102-1116
 - gonococcal, 6:1132
 - drainage of joints in, 6:1068, 1089-1090, 1093-1101, 1128
 - in children, 6:1109-1112
 - gonococcal, 6:1130-1139
 - hand in, 6:666
 - monitoring treatment of, 6:1081-1092
 - mycobacterial and fungal forms of, 6:1117-1129
 - caused by atypical mycobacteria, 6:1123-1124
 - mycotic, 6:1124-1128
 - tuberculosis, 6:1113-1114, 1117-1123
 - reasons for failure in treatment of, 6:1067
 - reconstruction of joints in, 6:1099-1100
 - rehabilitation in, 5:1010-1021
 - acute traumatic joint, 5:1020
 - arthritis of unknown etiology, 5:1011-1019
 - degenerative joint disease, 5:1019-1020
 - infectious arthritis, 5:1010-1011
 - metabolic arthritis, 5:1020-1021
 - Reiter's syndrome, 6:1140-1145, 1150, 1151
 - rheumatoid, *see* Rheumatoid arthritis
 - steroid therapy for, 5:1126
 - viral forms of, 6:1146-1153
- Arthropathy, neurogenic, with diabetes, 4:55-56
- Articulation, 4:783
- Ascariasis, treatment of, 6:157
- Ascites, 6:191-199
- genesis of, 6:178, 191, 193
 - treatment of, 6:193-199
- Aspirin therapy for pain, 5:1096-1103
- in analgesic combinations, 5:1117-1118, 1129
 - postpartum pain, 5:1172, 1173
 - side effects of, 5:1101-1103

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1368 / Cumulative Index

- special aspirin forms for, 5:1097-1101, 1173
- Asthma, 6:230, 233, 278-330
 - bronchial, *see* Bronchial asthma
 - clinical classification of, 6:279-285
 - definition of, 6:279
 - as drug reaction, 5:1103
 - immunologic mechanisms in, 6:284-285
 - laboratory studies in, 6:285-287
 - mortality in, 6:278-279, 283-284
 - perennial, in food allergy, 5:852-853
 - physiology of, 6:287-294
 - spirogram patterns in, 6:234
 - status asthmaticus, 5:782; 6:230, 279, 294-325, 354, 356-357
 - acid-base disorders, 6:317-322
 - antihistamine therapy, 6:324
 - case study, 6:292-294
 - clinical data, 6:281-282
 - corticosteroids in, 5:845-846
 - definition, 6:294
 - drug therapy, 6:300-306, 350, 351
 - gas exchange adequacy, 6:306-317, 357
 - management of secretions, 6:297-300
 - pathology, 6:282-284
 - therapy of infections, 6:322-324
- Ataxia, speech in, 4:797
- Atelectasis
 - avoidance of, in burned patient, 4:1274-1275
 - postoperative pain and, 5:1175
- Atherosclerosis
 - menopause and, 5:581-586
 - occlusive, in diabetic, 4:111-113
 - drug therapy for, 4:115-116
 - peripheral arteriography for, 4:114
 - prognosis for, 4:118
 - prophylaxis for, 4:115
 - pulse wave oscillography and, 4:114
 - surgery for, 4:116-118
 - primary biliary cirrhosis and, 6:212-213
 - vertigo from, 6:569-570
- Athetosis
 - speech in, 4:797
 - surgery for, 5:313-314
- ATN (acute tubular necrosis), *see* Renal failure
- Atopic dermatitis, 5:866-878
 - complications of, 5:876-877
 - differential diagnosis of, 5:866-867
 - identifying specific allergen in, 5:867-869
 - treatment of, 5:869-878
- whether an allergic disease, 5:775, 867
- Atropine
 - in Parkinson's disease, 5:285, 286, 291
 - for toxic neuropathy, 5:1244-1245, 1247
- Autism, infantile, 4:775
- Autoerythrocyte sensitization, 5:30-31, 459-460
- Autonomic neuropathy, 5:1229-1230
- Autonomic seizures, 6:1221-1222
- Autosomes, 4:838
- Axillary neuropathy, 5:1216-1217
- Azotemia
 - dietary sodium in treatment of, 5:626-634
 - magnesium deficiency with, 5:671
- Back pain
 - low, *see* Low back pain
 - regional-block therapy for, 5:1182
- BAL (British anti-lewisite, 2,3-dimercaptopropanol)
 - in heavy-metal reactions, 5:810
 - in Parkinson's disease, 5:322, 323-325
- BAL therapy for neuropathy
 - arsenic neuropathy, 5:1247
 - thallium neuropathy, 5:1247
- Barbiturates
 - addiction, 6:713-714
 - withdrawal from, 6:740
 - in analgesic mixtures, 5:1116
 - clinical pharmacology of, 4:679, 684
 - dependence on, 5:1124
 - narcotics and, for labor pain, 6:1166-1168
 - physicochemical properties of, 4:680
 - poisoning and, *see* Poisoning, barbiturate
 - See also* Phenobarbital
- Basal metabolic rate
 - low, and reduction in caloric expenditure, 4:1127
 - thyroid hormone and, 6:460
- Base
 - excess of, metabolic acidosis and, 5:656-657
 - loss of, metabolic acidosis and, 5:647, 649-650
- BCG vaccine, 5:888
- Bedsonia, arthritis and, 6:1150, 1151
- Behavioral changes after meningitis, 4:983
- Behavioral responses to immobilization, 5:908

- Belladonna alkaloids in Parkinson's disease, 5:284, 293, 295
- Bell's palsy, 5:1278-1284
definitive medical therapy for, 5:1281-1282
general management of, 5:1279-1280
late complications of, 5:1283
special tests for, 5:1280-1281
surgical therapy for, 5:1282
- Benzomorphan derivative therapy, 5:1147-1148
- Beriberi, infantile, 4:1038
- Bernard, Claude, 5:615
- Berylliosis, 6:108
- Beta-blocking agents, 4:247-248, 374-375, 381
- Bile
composition and stability of, 5:483-488
in gallstone disease, 5:487-488
- Bile ducts and gallstone formation, 5:488-489
- Biliary pain, drug for, 5:1147
- Biliary system, effect of morphine on, 5:1140
- Biliary tract, postcholecystectomy complications of, 5:528-540
- Bilirubin
decreased conjugation of, in newborn, 4:996-997
excretion of, gallbladder nonvisualization and, 5:501
unconjugated, and cerebral accumulation of, 4:995
- Bis-mono-isopropylamino fluorophosphine oxide neuropathy, *see* Mipafox neuropathy
- Bladder
atonic, 5:1229
care of neuropathic patient's, 5:1214, 1235
distended, 5:1088
disturbance of function of, 5:1180, 1199
dysfunction of, in diabetic neuropathy, 4:51-54
loss of control of, 5:1090
paralysis of, 5:1231
rupture of, 6:934
- Blastomycosis, 6:1124, 1125
- Bleaches as poison, 4:638-641
- Bleeding
gastrointestinal, in burned patient, 4:1286-1287
See also Blood; Hemorrhage
- Bleeding time, prolonged, as drug side-effect, 5:1102-1103
- Blepharospasm in Parkinson's disease, 5:319
- Blindness, *see* Vision, loss of
- Blood
arterial lactate in shock and, 4:281, 289-290
flow of, mechanism of, 4:371-372
gases in, in shock, 4:281, 296
occult loss of, as drug side-effect, 5:1101-1102
red cells of, 4:267-268
volume of, effect of surgery on, 5:1152
- Blood coagulation
defects of
acquired, 5:24-37, 363-383; *see also* De fibrination syndromes
aggravation of, 5:1118
hereditary disorders of
dental care, 5:93-110
diagnosis, 5:22-24, 33
genetic counseling, 5:125-133
psychiatric and social care, 5:111-124
surgical care, 5:61-83
therapy, 5:39-60
- Blood dyscrasias from drugs, 5:1106, 1109
- Blood levels
of drugs, 5:1097-1098, 1100, 1104
of sugar, *see* Glucose in blood
- Blood lipids, regulation of, 6:1302-1304
cholesterol, 6:1304-1306
fatty acids and triglycerides, 6:1306-1309
hypolipemic drugs, 6:1310-1311
liver disease and, 6:1352-1358
phospholipids, 6:1309-1310
- Blood pH, measurement of, 5:640-641
- Blood platelet disorders, 5:27-30, 95-96, 423-444

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1370 / Cumulative Index

- with bone-marrow disorders, 5:435-436
- after transfusions, 5:436-440
- See also specific disorders*
- Blood pressure
 - in shock, 4:281
 - transient fall in, 5:1254
 - variation of, as drug side-effect, 5:1158
- Body water, 5:617-624
 - baseline requirements for, 5:700
 - cellular, 5:621-624
 - extracellular, 5:618-621
 - potassium excess and, 5:667
 - of infants
 - amount, 5:617, 684-685
 - requirements, 5:685-688
 - magnesium deficiency from loss of, 5:670
- See also Fluid and electrolyte disorders; Water intoxication*
- Bowels
 - care of neuropathic patient's, 5:1214
 - dysfunction of
 - from regional blocks, 5:1180
 - See also Constipation; Diarrhea*
- Brachial plexus neuropathy, 5:1215-1216
- Bradykinesia, testing for, 5:259-260, 279
- Brain
 - abscess of, and meningitis, 4:978
 - emotional-response structures in, 5:1198-1199, 1202
 - intracranial pressure in, increased in pyrogenic meningitis, 4:900-901, 924-925
 - morphine distribution to, 5:1139
 - neuropathies affecting, 5:1231, 1232
 - sterotoxic thalamotomy on, 5:1206
 - swelling of, *see* Edema—cerebral
 - in tuberculosis meningitis, 4:944-945
 - See also specific parts of brain*
- Brain damage, 5:942-948
 - congenital, 5:944-947
 - psychologic examination in, 5:896-897
 - traumatic, 5:942-944
 - social reintegration of patient, 5:943-944
 - See also Stroke patients*
- Brain scan in epilepsy
 - radio pharmaceuticals, and, 6:1208-1209
 - results of, 6:1209-1212
- Bromide intoxication, withdrawal from, 6:739-740
- Bronchial asthma
 - antihistamines in, 5:839
 - corticosteroids in, 5:844, 845
 - in drug allergy, 5:805
 - meperidine therapy for, 5:1144
 - morphine therapy for, 5:1141
- Bronchiectasis, cor pulmonale and, 6:249
- Bronchitis, 6:233, 354
 - chronic, acidosis from, 5:653
 - cor pulmonale and, 6:249
- Bronchodilating drugs, 6:351-353
 - aerosols, 6:364
- Bronchodilation in airway obstruction, 4:1177
 - for burned patients, 4:1270
- Bronchoscopy in status asthmaticus, 6:295-296
- Bronchospasm
 - anaphylactic, 5:783, 784
 - treatment, 5:787, 789, 817
 - in burned patient, 4:1270
- Bruits in arterial obstruction, 4:389-392
- Buerger's disease, neuropathy with, 5:1267
- Buffered salicylate therapy for pain, 5:1098, 1101
- Burns
 - acute brain syndromes following, 4:1294
 - airway establishment with, 4:1263, 1267-1268
 - assisted ventilation, 4:1269
 - tracheal humidifier, 4:1269-1270
 - tracheostomy for, 4:1268-1269
 - airway trauma with, 4:1204
 - aldosterone activity with, 4:1207
 - blood volume reduction in, 4:1206
 - cause of, 4:1196
 - cell damage in, 4:1198, 1204
 - in children, 4:1298-1300
 - cold applications for, 4:1198, 1224
 - cold water treatment of, 4:1200-1202
 - colloid therapy for, 4:1232-1233, 1236, 1241
 - formulas for predicting colloid requirements, 4:1240-1241
 - initial infusion, 4:1236, 1240
 - urine volume, hourly measurement, 4:1240
- constricting, 4:1305
- deep, partial thickness of, 4:1307
- depth of, 4:1196-1197
- diagnosis of, 4:1245-1246
- edema formation with, 4:1198, 1204, 1206
 - bronchial, 4:1270
- encephalopathy and, related to in-

- jury, 4:1293-1294
- eschar
 - chemical debridement of, 4:1305-1306
 - mechanical debridement of, 4:1306-1307
- evaluation of, 4:1196-1202
- extent of body surface burned, 4:1196, 1246-1247
- first-degree, 4:1243, 1248
- fluid therapy for, 4:1196-1197
 - after initial replacement and resuscitation, 4:1230-1231
 - albumin in low-sodium diluent, 4:1219
 - balanced electrolyte solutions, 4:1221-1224
 - contraindicated in pulmonary-burn patients, 4:1278
 - for correction of acidosis, 4:1220-1221
 - dextran in saline, 4:1219
 - experimental and clinical basis, 4:1208-1218
 - formulas for predicting requirements, 4:1240-1241
 - initial, 4:1224-1226
 - laboratory studies, 4:1226-1229
 - plasma, 4:1214, 1219
 - plasmanate, 4:1219
 - rapid, and resultant edema, 4:1224-1225
 - sodium acetate, 4:1220
 - sodium bicarbonate, 4:1220, 1221
 - sodium chloride solution, 4:1219-1220
 - sodium lactate, 4:1220, 1221
 - whole blood, 4:1218-1219
- gastrointestinal bleeding with, 4:1286-1287
- hand, 4:1311
- hospital discharge and, 4:1296-1298
- hospital treatment of and recovery from, 4:1294-1296
- hypnotic therapy for, 4:1301-1302
- intracellular enzyme production in, 4:1204
- of joints, 4:1311
- late care of, 4:1312
- local therapy for, 4:1242-1261
- long-term management of, 4:1282-1289
 - metabolic acidosis with, 4:1207, 1220
 - neck, 4:1311
 - nutrition of patient with, 4:1285-1286
 - pain relief with, 4:1197-1198
 - pathophysiology of, 4:1203-1208
 - plastic therapy for, indications for, 4:1304-1312
 - positioning and splinting for, 4:1287-1289
 - potassium loss with, 4:1204
 - replacement therapy, 4:1223
 - primary excision for, 4:1304-1305
 - psychotherapeutic support of patient with, 4:1291-1302
 - in period of acute crisis, 4:1291-1294
 - role of psychiatrist, 4:1300-1302
 - pulmonary problems with, 4:1264-1266
 - avoidance of atelectasis, 4:1274-1275
 - bronchial edema, 4:1270
 - bronchospasm, 4:1270
 - clinical care, 4:1267-1278
 - edema phase (0-24 hours), 4:1266-1267
 - fluid therapy and lungs, 4:1278
 - heat and flame, 4:1264-1265
 - intratracheal antibiotic therapy, 4:1277
 - physical findings, 4:1265-1266
 - pneumonia phase (14-28 days), 4:1267
 - removal of noxious gases, 4:1272-1274
 - re-oxygenation, 4:1270-1272
 - sepsis, control of, 4:1275-1277
 - smoke and irritating gases, 4:1264
 - tissue slough and sepsis phase (3-14 days), 4:1267
 - replacement of fluid loss from, 5:704
 - respiratory problems with, 4:1263-1279
 - resuscitation from, systemic therapy for, 4:1203-1233
 - "rule of nines" and, 4:1243-1244, 1248

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
 Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
 Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1372 / Cumulative Index

- second-degree, 4:1243-1244, 1248
 skin grafts for, 4:1307-1311
 sodium loss from, after first 48 hours, 4:1231-1232
 third-degree, 4:1244-1245, 1248
 unhealed old, 4:1312
 excision of, delayed and staged, 4:1250-1251
 excision of, immediate, 4:1249-1250
 exposure method of treatment, 4:1253-1255
 first-aid therapy, 4:1247-1248
 initial cleansing, 4:1248-1249
 local care of, aims and principles, 4:1247, 1249
 management of, long-term, 4:1282-1284
 occlusive dressings, 4:1251-1253
 pathology, 4:1242-1245
 topical antibacterial therapy, 4:1255-1261; *see also specific drugs*
 Bursitis, septic prepatellar, 6:1112
 Caffeine therapy for pain, 5:1116, 1117, 1119; *see also* A.P.C. therapy for pain
 Calcium
 deficiency of, *see* Hypoparathyroidism; Uremia
 excess of, *see* Hypercalcemia
 idiopathic hypercalciuria and, 5:680
 menopausal osteoporosis and, 5:576-577, 680-681
 metabolic disorders of, 4:1007-1011
 in dialysis patient, 6:1062-1063
 in uremia, 6:1046-1049
 Calculi, urinary (calcium stones), *see* Kidney stones
 Caloric balance, positive, 4:1125-1127
 Caloric-protein malnutrition, magnesium deficiency with, 5:671
 Caloric tests, 6:601-602, 603-604
 Caloric therapy for neuropathy, 5:1259
 Calories, baseline requirement of, 5:701
 Cancer
 clergymen and treatment of, 6:894-895
 drug tolerance and, 5:1128-1129
 metastatic hypercalcemia due to, 5:681-682
 pain with, control of, 5:1089-1091
 regional-block therapy, 5:1180
 surgical procedures, 5:1200, 1203
 terminal stage, 5:1091, 1125
 thyroid nodules and, 6:534-549
 See also specific types of cancer
 Canker sore (recurrent aphthous stomatitis), 4:558-559, 567-570
 Carbamazepine therapy for neuralgia, 5:1273
 Carbohydrate metabolism disorders, 4:997-1007
 in uremia, 6:1049-1050
 Carbonic acid-bicarbonate system and pH, 5:639-640
 Carcinoma
 breast, pulmonary insufficiency with, 6:111
 cervical, hopelessness predisposition and, 6:653
 chorio-, hyperthyroidism with, 6:513
 prostatic, lymphedema secondary to, 6:386
 thyroid
 from radioiodine treatment, 6:502-503
 See also Cancer—thyroid nodules and
 See also Cancer
 Carcinomatous neuromyopathies, *see* Neoplastic neuromyopathies
 Cardiac arrest
 anaphylactic, 5:783
 treatment, 5:788, 789
 from poisoning, 4:608
 Cardiac arrhythmia, vertigo and, 6:572, 574-575
 Cardiac deficit in shock, 4:282-284
 Cardiac disability, 5:931-941
 balancing energy capacity and costs in, 5:932-935
 definitions of, 5:931-932
 exercise program in, 5:937-941
 physical rehabilitation in, 5:932-935
 social and psychological rehabilitation in, 5:936-937
 Cardiac failure, *see* Heart failure
 Cardiac output, measurement of, 4:279-280
 Cardiac tamponade, 4:129-130, 147, 157
 Cardiopulmonary disorders in obese patients, 4:1162-1179
 Cardiopulmonary syndrome of obesity, 4:1164-1165
 Cardiorespiratory functions in obesity, 4:1162-1163
 Cardiovascular function, postoperative, 5:1156, 1158-1159
 Cardiovascular problems
 from analgesics, 5:1157
 in obesity, 4:1443-1444
 Cardiovascular system, 4:270-271
 effect of morphine on, 5:1140-1141

- See also specific parts of cardiovascular system*
- Carisoprodol therapy for pain, 5:1115
- Carpal tunnel syndrome with neuropathies, 5:1211, 1232, 1234
- Cataracts, diabetic, 4:63
- Cation-anion metabolic disorders and mental retardation, 4:1039, 1043
- Causalgia, therapy for
specific, 5:1088
surgical, 5:1024
- Celiac plexus block therapy, 5:1182-1183, 1187, 1188
- Cellular fluids, 5:621-624
- Cellular type of reaction, fundamental mechanism of, 5:779-780
- Cellulitis and septic arthritis complicating osteomyelitis, 6:1112-1113
- Central nervous system
bleeding into, 5:57
effect of continuous pain on, 5:1086
hypoxia effects on, 6:19-21
paroxysmal vertigo and, 6:1295-1296
postshunt disturbances of, 6:187
renal failure and, 6:1015, 1042-1044
- Cerebral biopsy in epilepsy, indications for, 6:1213-1214
- Cerebral deficit, diagnosis of, 6:872, 874-877
- Cerebral palsy
rehabilitation in, 5:945-947
speech disorders of, 4:796-797
- Cerebral surgery to relieve pain, 5:1201-1202
- Cerebral vascular accidents, 5:1086
- Cerebral vascular lesions, *see* Stroke patients
- Cerebrospinal fluid examination
anticoagulation of CSF in, 4:881-883
cell counts in, 4:880-882, 885
Wright's stain, 4:883-884, 885-886
cellular response in CSF in, 4:933
CSF profile in, 4:879
infectious meningitides and, 4:891-895
noninfectious factors, 4:894
chloride ion determination in, 4:891
cultures of CSF in, 4:890
in epilepsy, 6:1183, 1195
- immunofluorescent technique of, 4:884, 887, 889
- lumbar puncture in, 4:880-881
effect on patient, 4:981-982
in meningoencephalitis, 4:879-896
positive blood reaction in, serologic test for syphilis and, 4:891
processing of CSF in, 4:880-891
protein determination in, 4:889
staining of cells in CSF in, 4:883-889
sugar determination in, 4:889
- Cerebrovascular diseases in diabetic, 4:99-102
- Cervical pain, regional-block therapy for, 5:1180
- Cervical vertigo, 6:570-573, 575-576
- Cesarean section, water and electrolyte disturbances after, 5:723
- Charcot joint with diabetes, 4:55-56
- Chelation for poisoning, 4:673-677, 710-711
- Chemotherapy in fungal infections of CNS, 4:951-957
- Chest (thoracic) pain
in pericarditis, 4:126-127, 137, 147, 153
postoperative, 5:1155-1156, 1174
regional-block therapy for, 5:1180, 1185
- Childhood trauma, 6:648
- Children
epilepsy in, 6:1182-1189
Graves' disease in, 6:511
infectious arthritis in, 6:1102-1116
gonococcal, 6:1132
- "Chloride depletion alkalosis," 5:657-658
treatment of, 5:659
- Chlorpropamide in maturity-onset diabetes in obese, 4:1187-1190
- Cholangitis
acute bacterial, 5:535-536
ascending, cholecystitis with, 5:523-524
nonsuppurative destructive, *see* Cirrhosis—primary biliary sclerosing, 5:537
- Cholecystectomy, 5:503-504
treatment after, 5:528-540
whether required, 5:494, 495-496

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1374 / Cumulative Index

- in silent gallstones, 5:508-512
- Cholecystitis
 - acute gaseous, 5:522
 - diagnosis of, 5:514-517
 - gallstones and, 5:480, 514-515
 - medical treatment of, 5:514-527
- Cholelithiasis, *see* Gallstone disease
- Cholera vaccine, 5:887
- Cholestasis, drug-induced, 6:144-146, 148-149
- Cholesterol
 - blood lipids and, 6:1304-1306
 - as cause of pericarditis, 4:158
- Cholesterosis, 5:489
- Choline salicylate therapy for pain, 5:1100, 1102
- Cholinergic urticaria, 5:835
- Christmas disease, 5:22-23
 - orthopedic management in, 5:84-92
 - surgical care in, 5:72-74
 - therapy for, 5:48-49
- Chromosomes
 - aberrations of, 4:843
 - studies of, 4:837-844
- Chylopericardium and pericarditis, 4:159
- Circulatory failure, *see* Hypertension
- Cirrhosis of the liver, 6:176-179
 - alcoholic, 6:121-122, 165-174, 200
 - treatment, 6:193-199
 - ascites in, 6:191-199
 - genesis, 6:178, 191-193
 - gastrointestinal bleeding in, 6:179-187
 - magnesium deficiency with, 5:671
 - primary biliary, 6:122, 205-214, 1355-1357
 - steroid effect on, 6:145
 - renal failure in, 6:200-203
- Claudication, intermittent, in occlusive arterial disease, 4:113; *see also specific disorders*
- Clergymen, assistance to physician by, 6:885-899
- Clonorchiasis, treatment of, 6:156
- Cocaine users, 6:714-715
- Coccidioidomycosis, 6:1124-1126
- Codeine, 5:1137, 1138, 1142
 - dependence on, 5:1111, 1123
 - side-effect of, 5:1112
 - in treatment of pain, 5:1110-1114
 - analgesic combinations, 5:1117-1118, 1129
- Cogentin (benztropine methanesulfonate), 5:293, 295-296
- Cogwheeling in Parkinson's disease, 5:269-270, 318
- Cold, use of, in rehabilitation, 5:911-912
- Cold urticaria, 5:834
- Colic, control of acute pain of, 5:1086, 1087, 1095
- Colitis, chronic ulcerative, morphine and, 5:1140
- Collagen diseases
 - restrictive pulmonary impairment in, 6:104-105
 - vascular diseases, 5:1268, 1279*See also specific collagen diseases*
- Coma
 - hepatic, *see* Hepatic coma
 - midbrain involvement in, 4:969
 - in neonatal hypoglycemia, 4:993
 - from poisoning, 4:610-611, 684-685
 - in Reye's syndrome, 4:1005
 - in tuberculosis meningitis, 4:945-946, 947-948
- Common bile duct
 - evaluation of, after cholecystectomy, 5:532-533
 - obstruction of
 - after cholecystectomy, 5:529, 533-535
 - with cholecystitis, 5:525
- Common peroneal neuropathy, 5:1223-1224
- Compressive neuropathies, *see* Traumatic and compressive neuropathies
- Concato's disease, 4:157
- Conditioning, drug addiction as, 5:1123-1124
- Congenital lysine intolerance and mental retardation, 4:1030-1031
- Congestive heart failure, *see* Heart failure—congestive
- Conjunctivitis, allergic
 - antihistamines for, 5:838, 839
 - corticosteroids for, 5:844
- Connective tissue disorders
 - hereditary, 5:447-448
 - restrictive ventilatory impairment in, 6:105-106
- Connective-tissue disease reactions from drugs, 5:805-806
- Constipation
 - with autonomic neuropathy, 5:1229-1230
 - from drugs, 5:1112, 1140
- Consumption coagulopathy, *see* Defibrination syndromes
- Contact dermatitis
 - delayed type of reaction in, 5:780
 - differential diagnosis of, 5:866-867
- Continuous lidocaine block therapy, 5:1183

- Conversion symptoms, sociopathy compared to, 6:709
- Convulsions from dextropropoxyphene, 5:1113
- Convulsive disorders
in children, with bacterial meningitis, 4:901-902
corticosteroids and, 5:850
as early sign of meningitis, 4:971-972
in neonatal tetany, 4:994
from poisoning, 4:612-613, 614, 663
tuberculosis meningitis and, 4:943-944
See also Epilepsy
- Cor pulmonale
causes of, 6:249-251
definition of, 6:248
in emphysema, 6:249, 342-343
obstructive respiratory disease and, 6:248-260, 357
restrictive respiratory failure and, 6:31-32
treatment of, 6:112-113, 258-260
- Coronary artery, restriction of flow in dog's, 4:309-312
- Coronary artery disease in diabetic, 4:97-99
- Coronary heart disease
clergyman and treatment of, 6:895
gallstones and, 5:496, 497
See also Angina pectoris; Atherosclerosis; Myocardial infarction
- Corticosteroid therapy
for acute idiopathic pericarditis of childhood, 4:190
with antibiotics, in pericarditis, 4:148
with antituberculous drugs, in pericarditis, 4:144-145
in infectious nonspecific pericarditis, 4:137-138
in pericarditis, with LE, 4:155
in postinfarction syndrome, 4:178-179
in postpericardiotomy syndrome, 4:173-174
in rheumatic pericarditis, 4:154
for septic shock, 4:329, 337
in tuberculous meningitis, 4:940-941
See also Adrenal corticosteroids
- Cosmetics, poisoning from, 4:643-646
- Cough, aerosol therapy for, 6:369-370
- Coumarin drugs, hemorrhagic complications from, 5:372-374
- Cretinism, 4:1044-1046
- Cryoglobulinemia, 5:35-36, 458-459
- Cryptococcosis, 6:1124, 1125
- Cushing's syndrome
childhood obesity and, 4:1152
potassium depletion with, 5:665
as side-effect of adrenal steroid therapy, 4:20
- Cyanosis, hypoxia and, 6:18-19
- Cycles, changes in health and, 6:649-650
- Cystathioninuria, 4:1034-1035
- Cystic duct remnants after cholecystectomy, 5:536
- Cystine
crystals of, 4:541
cystine stone disease, 4:465, 470, 539-548; *see also* Kidney stones
tests for, 4:539-540, 550
- Cystinuria, 4:539-552
- Cysts, pericardial, 4:208-209
- Cytotoxic (cytolytic) reactions, fundamental mechanism of, 5:778-779
- DDT neuropathy, 5:1247
- Defibrination syndromes
laboratory diagnosis of, 5:388-389
mechanism of, 5:387-388
nonobstetric varieties of, 5:386-387
pathophysiology of, 5:385-386
prognosis in, 5:398
treatment of, 5:384-400
- Deficiency neuropathy, 5:1249-1262
complications of, 5:1254
convalescent and long-term care of, 5:1260
prognosis for, 5:1260-1261
therapy for, *see* Alcoholic neuropathy—therapy for
- Degenerative neurologic disease, 5:1003-1009; *see also* Parkinson's disease
- Dehydration
in infants, 5:589-697

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1376 / Cumulative Index

- in labor, prevention of, 5:720
- in poisoning, 4:652
- in surgical patients, 5:705-708
- Delayed type of reactions, fundamental mechanism of, 5:779-780
- Delirium, 6:737-739
- Demerol, *see* Meperidine
- Dental care in hereditary disorders of blood coagulation, 5:93-110
- Depression
 - in acute illness, 6:736-737
 - in children, 4:775
 - circulatory, from poisoning, 4:687-689
 - etiology of, 4:545-546
 - masked, 6:688-694
 - psychotropic drugs in, 6:795-796, 801-804
 - signs of, 6:688-689
 - sociopathy compared to, 6:709
- Deprivation
 - cultural, 4:760-761
 - emotional, 4:760-761, 775
- Dermatitis
 - atopic, *see* Atopic dermatitis
 - contact, *see* Contact dermatitis
 - differential diagnosis of, 5:866-867
 - medicamentosa, 5:801-803
- Dermatophytosis with lymphangitis, 6:392-393
- Dermographism, 5:833
- Detergents as poison, 4:633-638
- Development, *see* Growth
- Dextran-40 for shock, 4:265, 266, 267, 272-273, 293, 328
- Dextran-80 for shock, 4:265, 293
- Dextroamphetamine therapy in obesity, 4:1142-1143
- Dextropropoxyphene
 - dependence upon, 5:1113
 - side-effects of, 5:1113-1114
 - in treatment of pain, 5:1112-1114
 - analgesic combinations, 5:1117
 - postpartum pain, 5:1173-1174
- Diabetes
 - corticosteroids in, 5:848
 - gallstones and, 5:497
 - neuropathy with, 5:1220, 1279
 - pre-diabetes, 4:1181
 - renal failure in, 6:1026
- Diabetes insipidus, nephrogenic, 4:1046-1047
- Diabetes mellitis, 4:87-88
 - arteriosclerotic complications of, 4:85-88
 - Charcot joint and, 4:55-56
 - cerebral vascular disease and, 4:99-102
 - coronary artery disease and, 4:97-98
 - diarrhea in, 4:49-51
 - exercise in, 4:94
 - eye changes in, 4:62-67
 - gangrene in, 4:102-106, 113, 114
 - hemochromatosis in, 4:83
 - hemorrhage (ocular) in, 4:65-66
 - impotence in, 4:54-55
 - insulin in, *see* Insulin
 - obesity and, 4:25-26
 - occlusive atherosclerosis and, 4:113
 - resistant, treatment of, 4:16-29
 - skin changes with, 4:82-83
 - skin changes suggesting, 4:75-82
 - skin diseases associated with, 4:73-84; *see also specific skin diseases*
 - smoking in, 4:94
 - vascular complications with, 4:85-106; *see also specific vascular diseases*
- Diabetes mellitus neuropathy, 4:59; 5:1226-1230
 - with acromegaly, 5:1232
 - lateral femoral cutaneous neuropathy with, 5:1223
 - orthostatic hypertension, 4:57-58
 - somatic, 4:44-47
 - treatment of, 4:44-60
 - varieties of, 5:1227-1230
 - visceral, 4:47-59, 111
- Diabetic ketoacidosis, 5:644
 - chronic insulin resistance with, 4:24-25
 - from inadequate antibodies, 4:25-27
 - magnesium deficiency with, 5:671
 - treatment of, 5:650-651
- Diagnosis
 - double, 6:663-664
 - psychologist's evaluation for, 6:871-885
 - tests for, role of, in deficiency neuropathy, 5:1254-1255
- Dialysis, 6:923, 946-949, 1054-1063
 - in the home, 6:984-999, 1058-1063
 - peritoneal, for poisoning, 4:606, 664, 665-667, 694
 - for poisoning, 4:606, 693-694
 - types of artificial kidneys in, 6:1057-1058
- Diarrhea
 - diabetic, 4:45-59; 5:1229-1230
 - in infants, water and electrolyte deficit from, 5:689-690
 - from mefenamic acid, 5:1109
 - metabolic acidosis in, 5:647
 - potassium depletion from, 5:665
- Diathermy, 5:909-911

- Diazepam**
 in degenerative neurologic disease,
 5:1005-1006
 dosage and preparation of, 6:1228
 epilepsy and, 6:1224, 1225
 side-effects of, 6:1226-1227
- Dibenzazepines** in Parkinson's disease,
 5:293, 297
- Diet**
 for citrullinemia, 4:1035
 for cystinuria, 4:543, 551-552
 for galactosemia, 4:1004-1005
 for hereditary fructose intolerance,
 4:1003
 for homocystinuria, 4:1031
 for hypercalcemia (idiopathic juvenile), 4:1007-1008
 for kidney stones, 4:480-481, 482-485
 for leucine-induced hypoglycemia,
 4:998
 for lipid-metabolism disorders,
 4:1011
 for maple syrup urine disease, 4:1030
 for obesity, 4:1125-1137
 in children, 4:1157-1158
 for oxaluria, 4:527, 528-529
 for phenylketonuria, 4:1032-1033
 for renal tubular acidosis, 4:1032-1033
- Digitalis**
 in congestive failure, 4:148-149
 childhood, 4:190-192
 in nonspecific pericarditis, 4:136, 208-209
 in shock, 4:312-314
- Dihydromorphine** therapy, 5:1137, 1138, 1142
- Diphenylheptane** derivative therapy,
 5:1148-1149
- Diphenylhydantoin** (Dilantin)
 dosage and preparation, 6:1228
 epilepsy and, 6:1223
 for neuralgia, 5:1272-1273
 side-effects of, 6:1226-1227
- Diphtheria**, neurologic complications
 of, 5:1265-1266
- Diphtheria vaccine**, complications from,
 5:885
- Diplococcus pneumoniae**, meningitis
 due to, 4:904-905, 918
- Dipyrone** therapy for pain, 5:1108
- Disability**
 definition of, 5:891
 superimposed, 5:906-908
See also Rehabilitation
- Disease**
 onset of, importance of life setting
 for, 6:643-655
 prevention of, 6:657
- Disseminated intravascular coagulation**,
 see Defibrination syndromes
- Disseminated lupus erythematosus**
 (DLE), thrombocytopenic
 purpura with, 5:432
- Disuse**, complications of, 5:906-908
- Dithizon** (diphenyl thiocarbazon) therapy for neuropathy,
 5:1247
- Diuresis**
 forced, for poisoning, 4:664-665, 690-692
 osmotic, in surgical patients, 5:705-706
- Diuretics**
 in ascites treatment, 6:194-198
 magnesium deficiency and, 5:670
 potassium deficiency and, 5:665
 in renal failure, 6:1024-1025
See also specific agents
- Diverticula** of pericardium, 4:208-209
- Diverticulosis coli**, gallstones and,
 5:497
- Dizziness**, *see* Vertigo
- Doctor-patient relationship**, *see* Physician-patient relationship
- DOPA** (DL-dihydroxyphenylalanine) in Parkinson's disease, 5:255, 298
- Down's syndrome**
 chromosomes in, 4:839
 maternal age and, 4:848
 probability and, 4:847-848
 speech disorders in, 4:796
- Drainage**, pericardial, 4:139, 141
- Dressler's syndrome** in acute pericarditis, 4:128
- Drug addiction** (compulsive drug use)

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1378 / Cumulative Index

- to analgesics, 5:1136, 1141, 1142, 1144, 1147, 1176
- codeine, 5:1111, 1123
- morphine, 5:1139
- pentazocine, 5:1132
- clergyman's role in, 6:890-891
- as conditioned behavior, 5:1123-1124
- defined, 5:1121-1122
- placebo response and, 5:1128
- prevention of, 5:1123-1124, 1131
- recognition and management of, 6:704, 710-718
- resulting from medical treatment, 5:1122-1126, 1130, 1202
- patient's fear of addiction, 5:1129
- unrelated to painful illness, 5:1133
- withdrawal from, 6:742
- Drug administration route for postoperative patient, 5:1157-1158
- Drug allergy, 5:775, 792-813
- cytotoxic reactions in, 5:779
- description of, 5:794-796
- diagnosis of, 5:797-801
- skin tests, 5:799-800, 808-809
- in vitro tests, 5:800-801
- immunochemical mechanisms of, 5:796-797
- manifestations of, 5:801-806
- prevention of reactions from, 5:806-810
- desensitization, 5:780, 809
- "Medic-Alert" information, 5:790, 809-810
- records, 5:790, 809, 819
- toxic-complex type of reaction in, 5:779
- treatment of, 5:810-812
- emergency kit, 5:807
- urticaria treatment, 5:826-827
- Drug combinations, *see* Analgesic drugs, combinations and mixtures of
- Drug dependence
- on carisoprodol, 5:1115
- on codeine, 5:1111, 1123
- defined, 5:1122
- on dextropropoxyphene, 5:1113
- non-medical, 5:1132-1133
- on opiates, *see* Opiate dependence
- See also* Drug addiction
- Drug-induced neuropathies, treatment of, 5:1237-1240
- general scope of treatment, 5:1237-1238
- varieties of neuropathies, 5:1238-1240
- Drug interactions and postoperative pain, 5:1162
- Drug reactions
- allergic, *see* Drug allergy
- classification of, 5:792-796
- definition of, 5:792-793
- Drug tolerance
- toward morphine, 5:1139, 1141
- toward narcotics, 5:1121-1122
- cross-tolerance, 5:1129-1130
- developing, 5:1122
- management of, 5:1128-1129
- toward pentazocine, 5:1132
- Drugs
- anticonvulsant, 6:1217, 1222-1231
- hyperkinesia and, 6:1236-1244
- labelling of, 5:808
- Duchenne muscular dystrophy
- enzyme determination in, 5:1036
- rehabilitation in, 5:1039-1042
- types of, 5:1037-1039
- Dwarfism, hypopituitary, 5:145-149
- Dying patients
- clergymen and, 6:897-898
- management of, 6:746-759
- Dysmenorrhea
- psychodynamic concepts of, oral contraceptives and, 5:587
- relief of pain of, 5:1095, 1116, 1204
- Dyspepsia from drugs, 5:1101, 1109
- Dysproteinemias, 5:455-459
- Dysrhythmia, 6:1193
- Dystonia musculorum deformans, surgery for, 5:314
- Dystrophy, 5:1036-1046
- characteristics of, 5:1036-1037
- forms of, 5:1024-1045, 1233; *see also* Duchenne muscular dystrophy; Sympathetic dystrophies
- Ears, pain in, surgical relief from, 5:1205
- Echinococcus disease of the liver, treatment of, 6:157-160
- Echocardiogram, 4:197-204
- Echoencephalography in epilepsy, 6:1214-1215
- Eczema
- antihistamines for, 5:839-840
- corticosteroids for, 5:844, 845
- Eczema herpeticum as complication of atopic dermatitis, 5:876-877
- Eczema vaccination, 5:884
- as complication of atopic dermatitis, 5:876
- Edema
- angioneurotic, *see* Angioneurotic edema
- in burns, 4:1198
- cerebral, from meningitis, 4:968-971

- acute, in meningococcal meningitis, 4:935
- coma and, 4:969
- laryngeal, as drug reaction, 5:1112
- osmotic treatment of, 4:972
- pulmonary, drug therapy, 5:1144, 1244
- respiratory disorder and, 4:973-974
- tissue, pain of, 5:1174
- Effusions
 - pericardial
 - in infectious nonspecific pericarditis, 4:137
 - pericardiosentesis, for relief, 4:174-175, 177
 - in pericarditis with systemic disease, 4:147, 148, 153-154
 - relief of cardiac compression, 4:148
 - ultrasound and, 4:197-204
 - subdural, in meningitis, 4:906-907, 936-937, 977-978
- Electrocardiography, potassium excess in, 5:668
- Electroencephalography
 - for epilepsy, 4:803-804, 805, 807, 811, 814-815
 - age modification, 6:1183, 1192-1193
 - examples, 6:1196-1207
 - recording, 6:1190-1192
 - rhythms, abnormal, 6:1193-1194
 - as therapy aid, 6:1194-1195
 - infantile spasms and, 4:812, 813
 - petit mal and, 4:808, 809
 - psychomotor seizures and, 4:806
- Electrolytes
 - baseline requirements for, 5:701
 - disorders of, *see* Fluid and electrolyte disorders
 - in infants, 5:688-689
 - renal function and, 5:626-627
- Electronystagmography, 6:602-604, 605
- Embolism
 - arterial, 4:359-361, 412, 414
 - surgery for, 4:359-361
 - fat, 5:36
 - multiple, neuropathy with, 5:1267-1268
- Emergencies
 - allergic, *see* Allergic emergencies
 - respiratory, 5:924
- Emetic treatment
 - of neuropathies, 5:1240-1241, 1244, 1246, 1247
 - for poisoning, 4:706
- Emphysema, 6:233, 268, 331-345, 354
 - characteristics of, 6:331-334
 - chronic obstructive, acidosis from, 5:653
 - cor pulmonale and, 6:249, 342-343
 - pulmonary, morphine dosage with, 5:1141
 - spirometry measures in, 6:234, 238-239
 - treatment of, 6:334-342, 347, 356
- Encephalitis lethargica, 5:284
- Encephalomyelitis from immunizations, 5:882-883, 884, 885
- Encephalopathies
 - bilirubin, 4:996-997
 - hepatic, *see* Hepatic coma
 - after meningitis, 4:968-972
- Enderectomy of femoral artery, 4:400
- Endocarditis, meningococcal disease and, 4:937
- Endolymphatic hydrops, *see* Meniere's disease
- Endotoxin in septic shock, 4:271, 321-344, 907-909
- Endotracheal intubation
 - in emphysema, 6:336, 341-342
 - in status asthmaticus, 6:296
- Enteric-coated salicylate therapy for pain, 5:1099, 1101
- Enteropathy, diabetic, 4:49-51
- Epidemiology of noninfectious clinical syndromes, 6:657
- Epilepsy
 - defined, 6:1179-1181
 - diagnostic procedures in, 6:1190-1215
 - hyperkinesia in children with, 6:1233-1245
 - pseudoretardation and, 4:801-818
 - psychiatric complications of, 6:1247-1261
 - vertiginous, 6:585-587

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
 Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
 Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1380 / Cumulative Index

- Epistaxis, 5:55
- Eponychium, chronic inflammation of, in diabetic, 4:80
- Epsilon aminocaproic acid (EACA) in abruptio placentae with defibrination, 5:411
- in primary fibrinolysis, 5:395-396, 398
- Erb's palsy from brachial plexus injury, 5:1215
- Ergotamine for neuralgia, 5:1275-1276
- Erosio interdigitale blastomycetica, 4:79-80
- Erythema
- anaphylactic, 5:783, 784
- in drug allergy, 5:802
- infectiosum, polyarthritis with, 6:1149-1150
- Estrogen
- cancer and, 5:564-570
- psychologic effects of, 5:587
- treatment of menopause with, 5:545-546, 551-562
- menopausal osteoporosis, 5:576, 681
- with psychiatric treatment, 5:591
- vascular disease and, 5:581-586
- Ethioheptazine, 5:1144
- in treatment of pain, 5:1114
- Ethosuximide
- dosage and preparation of, 6:1228
- epilepsy and, 6:1224
- side-effects of, 6:1226-1227
- Ethylene glycol, poisoning from, 5:646, 653
- Etiocolanolone fever, 4:156
- Eunuchism, definition of, 5:185
- Eunuchoidism, 5:185
- hypogonadotropic, 5:149-151
- Ewart's sign in acute pericarditis, 4:128
- Exchange transfusion
- in hemolytic disease of newborn, 4:995-996
- for poisoning, 4:606-607
- Exercise
- functional, 5:916
- therapeutic, 5:913-916
- in arthritis, 5:1010, 1012, 1015-1016, 1019, 1021
- in cardiac disabilities, 5:937-941
- contraindications to, 5:915-916
- hydrotherapy as adjunct, 5:915
- in low back pain, 5:1028-1035
- in peripheral nerve syndromes, 5:999
- in respiratory disabilities, 5:928-929
- in spinal cord injuries, 5:958-960
- for stroke patients, 5:990
- Exotoxins in septic shock, 4:321-322
- Eyes
- in alkali poisoning, 4:731
- effect of neurosurgery on, 5:1204-1205
- Graves' disease and, 6:516-529
- neuropathies affecting, 4:48, 62-72; 5:1228, 1232
- in Parkinson's disease, 5:310, 316-320
- vertigo and, 6:590-591
- See also* Vision; *specific eye disorders*
- Facial neuralgia
- atypical, 5:1276-1277
- surgical relief of, 5:1205
- Family, 6:806-820
- clergyman's counseling of, 6:891-892
- disability and, 5:897-898
- of dying patients, 6:751-752
- general physician's psychotherapy of, 6:783-789, 806-807, 813-819
- poorly adapted, 6:648
- Fanconi syndrome
- magnesium deficiency in, 5:671
- potassium deficiency in, 5:666
- Farmer's lung, 6:108
- Fascioliasis, treatment of, 6:156-157
- Fasting
- effect of, on adipose tissue, 4:1085-1087
- in obese children, 4:1157-1158
- Fat
- in diabetic diet, 4:33, 86-87
- in glycogen storage disease, 4:1002
- in ketotic hypoglycemia, 4:998-999
- Fat embolism, 5:36
- Fatty acids and blood lipids, 6:1306-1309
- Febrile convulsions
- characteristics of, 6:1182-1185
- prophylactic treatment of, 6:1187-1189
- treatment of, 6:1185-1186
- Feet
- care of, in arterial disease, 4:354-357
- neuropathic pain in, 5:1224-1225, 1231
- with deficiency neuropathy, 5:1253, 1259
- with diabetic neuropathy, 4:46; 5:1229
- with toxic neuropathy, 5:1240
- ulcers of, *see* Ulcers, of feet
- Femininity index, 5:559
- Femoral arteriosclerosis, surgery for, 4:399-400; *see also* Arteriosclerosis, occlusive

- Femoral neuropathy, 5:1222-1223
 Fetal death and defibrination, 5:411-415
 Fever in drug allergy, 5:804
 Fever blister (recurrent labial herpes), 4:556, 558-559, 562-564
 Fibrin-stabilizing factor deficiency
 diagnosis of, 5:22-23
 surgical care in, 5:79
 therapy for, 5:52
 Fibrinogen deficiency, *see* Afibrinogenemia
 Fibrinolysis, primary, 5:384, 395-396
 Fibrosis, pulmonary, 6:104, 113
 breathing exercises in, 6:112
 spirogram patterns in, 6:234
 Finger webs, yeast infection of, 4:79-80
 Fistula
 arteriovenous, 4:409-410
 cholecystitis with, 5:522-523
 meningitis and, 4:978-979
 Flail chest, respiratory failure with, 6:36-37
 Fluid and electrolyte disorders, 5:615
 in infants, 5:684-697
 from acidosis, 5:690-692
 from diarrhea, 5:689-690
 treatment for, 5:692-697
 physiologic basis of, 5:617-624
 in pregnancy, 5:714-724
 abortion, 5:721-723
 hemorrhage, 5:720-721
 nausea and vomiting, 5:714-715
 surgically induced disturbances, 5:723-724
 toxemia, 5:716-720
 in surgical patients, 5:699-713
 abnormal loss, 5:702-704
 in surgical patients, 5:699-713
 baseline requirements, 5:699-702
 preexisting deficits and excesses, 5:704-709
 See also specific disorders
 Fluoride ingestion and menopausal osteoporosis, 5:577-578
 Focal seizures
 focal-motor, 6:1220
 drugs effective against, 6:1222-1224
 focal-sensory, 6:1220-1221
 psychomotor, 6:1221
 drugs effective against, 6:1228
 Food allergy, 5:775, 776, 852-861
 atopic dermatitis and, 5:868
 diagnosis of, 5:854-857, 863-864, 868
 immunologic characteristics of, 5:853-854
 manifestations of, 5:852-853
 treatment of, 5:857-861, 868
 hyposensitization, 5:859, 868
 of urticaria, 5:827-829
 Freud, Sigmund, on love and disease, 6:653-654
 Friction rub in pericarditis, 4:127, 153-154, 157
 Friedrich's ataxia, 5:1003
 Frozen shoulder in stroke patients, 5:983, 989
 Fructose intolerance, hereditary, 4:1003
 Furadantin-induced neuropathy, 5:1238-1239
 Gait analysis, 5:895
 Gait in Parkinson's disease, 5:264-268, 280
 Galactosemia, 4:1003-1005
 Gallbladder
 agenesis of, 5:501
 carcinoma of, gallstones and, 5:497-498, 504
 cholesterolosis of, 5:489
 empyema of, 5:522
 inflammation of, *see* Cholecystitis;
 Gallstone disease
 nonfunctioning, 5:500-504
 porcelain, 5:498
 rupture of, with bile peritonitis and abscess formation, 5:524-527
 Gallstone disease (cholelithiasis)
 cause of, 5:480-492
 changes in bile in, 5:487-488
 incidence of disability from, 5:496
 natural history of, 5:493-499
 other disorders and, 5:496-498
 prevalence of, 5:505
 roentgenographic diagnosis of, 5:500-503
 silent, *see* Gallstones, silent
 surgical treatment of, *see* Cholecystectomy

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
 Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
 Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1382 / Cumulative Index

- Callstones
 - composition and structure of, 5:480-483
 - in cystic duct remnant, 5:536
 - formation of, 5:488-490
 - incidence of, 5:528
 - silent, 5:495, 505-513
 - spontaneous disappearance of, 5:494-495
 - whether they "get worse," 5:493-495
- Ganglion block therapy, 5:1282-1283
- Gangrene
 - diabetic, 4:102-106, 109-111, 113
 - in occlusive arterial disorders, 4:351, 352, 361-367
 - in Raynaud's disease, 4:367-368
 - vasodilation for, 4:378
- Gargoylism, 4:1005-1006
- Casserian ganglion injection for neuralgia, 5:1274
- Gastric achlorhydria, vitamin therapy for, 5:1260
- Gastrointestinal allergy, 5:775-776, 861-864
- Gastrointestinal tract
 - absorption of drugs in, 5:1098, 1100, 1138-1139
 - in anaphylaxis, 5:783
 - bleeding from, 6:179-187
 - in diabetic neuropathy, 4:48-51
 - disturbance of function of, 5:1174
 - effect of morphine on, 5:1139, 1140
 - effects of antibiotics on, 5:793
 - fluid and electrolyte losses from, in surgical patients, 5:702-703, 706-708
 - hypoxia effects on, 6:21
 - massive hemorrhage of, 5:1102, 1109, 1118
 - occult bleeding of, 5:1101-1102
 - postoperative pain in, 5:1174
 - See also *specific parts of gastrointestinal tract*
- Gastroparesis diabeticorum, 4:48-49
- Genetic counseling, 4:844-851; 5:238-239
 - in hereditary disorders of blood coagulation, 5:125-133
 - in Huntington's disease, 5:342-343
- Genetics
 - investigation of, 4:837-844
 - mental retardation and, 4:837-851
 - obesity and, 4:1091-1092, 1100-1104, 1126
- Genitourinary tract changes in diabetic neuropathy, 4:51-53
- Gentamicin for burn infections, 4:1258-1259
- Geriatrics, clergyman's role in, 6:892-893
- Giving-up, predisease, 6:645-647, 651-654
- Glaucoma, control of pain of, 5:1087
- Glomerulonephritis, 6:925
 - from immunization, 5:883
- Glossopharyngeal neuralgia, 5:1275
- Glucose in blood
 - cholesterol and, 5:1103
 - 6-phosphatase deficiency, 4:1001-1002
- Glue sniffing, 6:716
- Glycogen storage disease, 4:1001-1002
- Glyoxylate
 - oxidation of, to oxalate, 4:527-528
 - pool of, reduction of, 4:526-527
- Goiter
 - "iodide," 6:450
 - nodular, and cancer, 6:534-549
- Gold thioglucose in experimental obesity, 4:1090
- Gonadal dysgenesis, 5:218-226
- Gonococcal arthritis, 6:1130-1139
- Gout, 5:1230
 - acute, treatment of, 5:1087
 - pericarditis and, 4:159
 - rehabilitation in, 5:1020-1021
 - in renal failure, 6:1045-1046
 - drugs in treatment of, 6:1027-1028
 - uricemia and, 4:531, 534-535, 536
- Grand mal seizures, 6:1217-1218
- Gonococcal arthritis, 6:1222-1224
- Graves' disease, 6:497-515
 - dermatopathy of, 6:529-531
 - diagnosis of
 - LATS, 6:452-453
 - triiodothyronine suppression test, 6:453
 - drug treatment of, 6:504-508
 - ophthalmopathy of, 6:516-529
 - radioiodine treatment in, 6:499-504, 513-514
 - thyroidectomy, 6:497-499
 - thyroiditis coexistent with, 6:492
- Group therapy, 6:821-841
 - in alcoholism, 6:768-772
 - "group psychoanalysis," 6:838-839
 - how conducted, 6:822-827
 - individual psychotherapy compared to, 6:837-838
 - practicing physician and, 6:839-840
 - therapeutic process in, 6:827-837
- Growth
 - diseases affecting
 - adrenal cortex diseases, 5:168-183
 - ovarian diseases, 5:205-217
 - pituitary diseases, 5:139-152

- testicular diseases, 5:184-204
 thyroid diseases, 5:153-167
 disorders of, 5:218-240; *see also specific disorders*
 thyroid hormone and, 6:460
 Growth hormone, fat-mobilizing properties of, 4:1088
 Guillain-Barré syndrome, 5:1264-1265
 respirator and airway care in, 5:1265
 Gynecological analgesia, *see* Analgesic therapy, for obstetric and gynecologic patients
- Hageman trait
 diagnosis of, 5:22-23
 surgical care in, 5:74-75
 therapy for, 5:49-50
 Halothane, hepatic reaction following, 6:136, 138, 147
 Hamman-Rich syndrome, 6:104, 113
 Hand in diagnosis, 6:665-666
 Hands in Parkinson's disease, 5:259-261, 279
 Handwriting in diagnosis of Parkinson's disease, 5:260
 "Hard water" syndrome, 5:673
 Hashimoto's thyroiditis, 6:484-492
 described, 6:485
 perchlorate discharge in, 6:448
 plasma thyroid antibodies in, 6:459
 treatment of
 hormone therapy, 6:490-491
 surgery, 6:491-492
 Hay fever
 antihistamines for, 5:840-841
 drug reaction and, 5:1103
 urticaria with, 5:830
 Head injury, vertigo after, 6:587-590, 609-611
 Head pain, surgical relief of, 5:1199, 1200
 pain from tumors, 5:1205-1206
 Headache
 acute, 5:1086
 as drug side-effect, 5:1161
 migraine, 5:1087, 1117
 Hearing, evaluation of, in disability, 5:898
 Heart
 changes in, in meningitis, 4:973
 compression of, in pericardial effusion, 4:148
 effect of continuous pain on, 5:1086
 in sarcoidosis, 4:151
 surgery on, and postpericardiotomy syndrome, 4:170-176
 transverse diameter of, in obese, 4:1163
 Heart disease
 coronary, clergymen and treatment of, 6:895
 hand in, 6:666
 Heart failure
 congestive
 azotemia with, 5:631-632
 in diabetes, 4:94
 digitalis in, 4:94, 148-149, 190-192
 in nonspecific pericarditis, 4:136
 in obesity, 4:1172-1173
 in obstructive pulmonary disease, 6:357
 renal failure and, 6:929-930, 942-943, 1053
 vertigo from, 6:572, 574-575
 Heat, use of, in rehabilitation, 5:909-911
 Helplessness, 6:645-654
 therapeutic implications of, 6:652
 Hemarthrosis, 5:54-55, 85-88
 Hematologic reactions to drugs, 5:804
 Hematomas, subdural, 4:825-826
 Hematuria, therapy for, 5:55-56
 Hemiplegics, *see* Stroke patients
 Hemochromatosis
 associated pericarditis and, 4:159
 in diabetes, 4:83
 Hemodialysis, *see* Dialysis
 Hemolytic anemia
 drugs causing, in certain individuals, 5:794-795
 gallstones and, 5:496, 497
 Hemolytic disease, neonatal, 4:996
 Hemolytic reaction to aniline derivatives, 5:1118
 Hemophilia
 circulating anticoagulants after treatment for, 5:376-379
 diagnosis of, 5:22-24
 orthopedic management in, 5:84-92

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
 Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
 Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1384 / Cumulative Index

- psychiatric and social care in, 5:111-124
therapy for, 5:43-48
- Hemophilus influenzae*, meningitis from, 4:902-904
- Hemorrhage
arterial, 4:405-411
gastrointestinal, 4:663-664, 676
massive, 5:1102, 1109, 1118
ocular diabetic, 4:65-66
with vascular neuropathy, 5:1268
- Hemosiderosis, idiopathic pulmonary, 6:104
- Hemostasis
diagnosis of disorders of, 5:17-37
physiology of, 5:11-17, 94-95
See also Blood coagulation
- Henderson-Hasselbach equation, 4:1207; 5:640, 642, 647; 6:317
- Henoch-Schönlein purpura, 5:33-35, 449-453, 803, 853
- Heparin therapy in defibrination syndrome, 5:393-394, 398
in abruptio placentae, 5:410-411
hemorrhagic complications, 5:374-376, 394
- Hepatic cell dysfunction, gallbladder nonvisualization from, 5:501
- Hepatic coma, 6:131-141
diuretic agents and, 6:198
physiologic bases of, 6:131-132
treatment of, 6:132-140, 151
- Hepatitis, 6:123-130
alcoholic, 6:168
chronic, 6:122, 125
coma in, 6:136-138, 151
drug-induced, 6:121, 136, 138, 142-152
etiology of, 6:124
fulminant, 6:123-124, 137-140
from phenylpyrazoles, 5:1108
prophylaxis for, 6:125-126
treatment of, 6:121, 126-129
- Hepatolenticular degeneration, 4:1039-1042
- Hereditary hemorrhagic telangiectasia, 5:444-447
- Heroin
for labor pain, 5:1167
as potent analgesic, 5:1138, 1141-1142
- Herpes simplex, atopic dermatitis and, 5:876-877
- Herpes simplex virus, 4:556, 560
- Herpes zoster
neuropathy with, 5:1266
- See also* Primary herpes with oral ulcers
- Herpetic gingivostomatitis, 4:555-561
- Herxheimer reaction, 5:793
- Hiatus hernia and gallstones, 5:497
- Histamine release
nonimmunologic, 5:794
symptoms resulting from, 5:784
- Histiocytosis X, pulmonary, treatment of, 6:110-111
- Histoplasmosis, 6:1124-1126
- History taking, 6:646-647, 656-687
associative technique of, 6:658, 781
illustrations of, 6:681-684
as interviewing, 6:662-663
physician as central figure in, 6:660-661
- See also* Interviewing
- Hives, *see* Urticaria
- Hodgkins disease, respiratory failure in, 6:40
- Homeostasis, importance of body fluids in, 5:615
- Homocystinuria, 4:1031
- Hookworm infections, *see* Ankylostomiasis
- Hopelessness, 6:645-654
therapeutic implications of, 6:652
- Hormonal therapy
ACTH, *see* Adrenocorticotrophic hormone therapy
psychologic effects of, 5:587, 593-594
treatment of menopause by, 5:550-563
menopausal osteoporosis, 5:576, 681
objections to, 5:545-546
with psychiatric treatment, 5:590-595
regulation of dosage, 5:554-559
- Horner's syndrome in bronchial plexus injury, 5:1216
- Horse serum antitoxin, 5:786, 807-808
- Huntington's disease
classification of, 5:333
diagnosis in, 5:332, 346-347
genetic counseling for, 5:342-343
prevalence of, 5:334
prognosis in, 5:350
psychiatric treatment of, 5:344-345
reproductive control in, 5:344-345
surgical therapy in, 5:340
treatment of, 5:256, 332-350
- Hydatidiform mole, hyperthyroidism with, 6:513
- Hydralazine-induced neuropathy, 5:1239

Cumulative Index / 1385

- Hydration in reduction of airway obstruction, 4:1173
- Hydrocephalus, 4:819-825
meningococcal disease and, 4:937, 982
- Hydrogen ions
in acid-base regulatory system, 5:636-638
types of derangements, 5:641-642
- metabolic alkalosis from loss of, 5:655-656, 659-660
- Hydrotherapy as adjunct to therapeutic exercise, 5:915
- Hydroxykynureninuria, 4:1034
- Hymenoptera sensitivity, *see* Insect sting reactions
- Hyperaldosteronism, *see* Aldosteronism
- Hyperbilirubinemia, neonatal, 4:995-997
- Hypercalcemia
calcium stones and, 4:468-469
due to metastatic carcinoma and myeloma, 5:681-682
hyperparathyroidism and, 4:489, 1010; 5:682-683
idiopathic infantile, 4:1007-1008
magnesium deficiency with, 5:670-671
- Hypercalciuria
calcium stones and, 4:468-470
idiopathic, 4:469; 5:680
- Hypercapnia, 6:239
in status asthmaticus, 6:317-319
treatment of, 5:654
- Hyperglycemia
in human obesity, 4:1093
in meningitis, 4:974-975
mental retardation associated with, 4:1029
- Hyperinsulinemia in obesity, 4:1093
- Hyperkalemia in renal failure, 6:940, 1040-1042
- Hyperkinesia
drug therapy and, 6:1236-1249
etiology of, 6:1233-1234
parent counseling, 6:1244-1245
symptom complexes associated with, 6:1234-1236
teacher counseling, remedial education and psychotherapy, 6:1245
- Hyperalpalipoproteinemia, 6:1324
- Hyperlipidemia
dietary treatment of, 6:1328-1340
drug treatment of, 6:1341-1350
mechanisms involved in, 6:1313-1325
- Hyperlipoproteinemia, type I, 6:1317-1319, 1332-1333
- Hyperlipoproteinemia, type II, 6:1319-1321, 1333-1334
- Hyperlipoproteinemia, type III, 6:1321-1322, 1334-1336
- Hyperlipoproteinemia, type IV, 6:1322-1323, 1334-1336
- Hyperlipoproteinemia, type V, 6:1323-1324, 1334-1336
- Hypernatremia, 4:1042-1043
- Hyperoxemia in cor pulmonale, 6:255, 259-260
- Hyperparathyroidism
calcium stones and, 4:466-469, 497
diagnosis of, 4:489-499
hypercalcemia and, 5:682-683
magnesium deficiency with, 5:671
surgical treatment of, 4:489-492
See also Kidney stones
- Hyperperia in poisoning, 4:652
- Hyperplasia, adrenal, congenital, 5:168-174
- Hyperpotasemia, 5:667-669
treatment for, 5:668-669
- Hyperpyrexia, 4:664
- Hypertension
arterial, 5:1279
cranial, from poisoning, 4:611, 614
in diabetes, 4:37-38, 87, 93
in obese patients, 4:1143-1144
pulmonary, in cor pulmonale, 6:251-254
in renal failure, 6:1050-1052
vertigo from, 6:572
- Hypertensive cardiovascular disease
and artificial kidney, 6:1062-1063
- Hypertensive cerebral hemorrhage
symptoms of, 5:974
See also Stroke patients
- Hyperthermia in meningitis, 4:974
- Hyperthyroidism, 5:163-166
hand in, 6:665

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1386 / Cumulative Index

- See also Graves' disease; Plummer's disease
- Hyperuricemia, 4:1036-1037
- Hypervolemia, 4:1029-1030
- Hypnotic drugs, 5:1116, 1119
- Hypocalcemia
- mental retardation and, 4:1010-1011
 - renal tubular acidosis and, 4:515-516, 517
 - transfusion-induced, 5:381-382
- See also Hypoparathyroidism; Uremia
- Hypoglycemia
- with glycogen disease, 4:1001-1003
 - idiopathic, spontaneous, 4:999-1001
 - in infants of diabetic mothers, 4:993-994
 - with ketosis, 4:998-999
 - leucine-sensitive, 4:997-998
 - as metabolic neuropathy, 5:1230
 - in neonatal period, 4:988, 991-994
 - nocturnal, 4:17
 - obesity and, 4:1128
 - prevention of, in cerebral vascular disease, 4:100
 - as secondary to steroid therapy, 4:19
 - from sulfonylurea therapy, combined with insulin, 4:22
- Hypogonadism, 5:185-186
- Hypokalemia
- after amphotericin B therapy, 4:953
 - renal tubular acidosis and, 4:515-516
- Hypolipemic drugs, 6:1310-1311
- Hyponatremia
- meningitis and, 4:975
 - mental retardation and, 4:1043
 - in poisoning, 4:652
 - in renal failure, 6:1040
- Hypoparathyroidism
- chronic idiopathic, 4:1008-1010
 - idiopathic, 5:230-237
 - treatment of, 5:676-678
- Hypophosphatasia, 4:1042
- Hypophysectomy in Graves' ophthalmopathy, 6:521
- Hypopituitarism, 4:1046
- Hypopituitary dwarfism, 5:145-149
- Hyposensitization
- to insect sting reactions, 5:799, 815, 818-820
 - in urticaria, 5:833
- Hypotension
- anaphylactic, 5:783, 784-785
 - treatment, 5:787-788, 817-818
 - meningitis and, 4:973
 - orthostatic in diabetic neuropathy, 4:57-58
 - renal failure and, 6:929-930
- Hypothalamic-pituitary axis, damage to, from meningitis, 4:981
- Hypothalamus
- lesions of, in childhood obesity, 4:1152
 - pleasure-giving center in, 4:1117-1118
 - punishment pain system in, 4:1118
 - satiety center of, 4:1117
 - TSH regulation by, 6:451
- Hypothermia and intravenous injections, 5:1157
- Hypothyroidism, 5:155-163
- cholesterol level in, 6:460
 - differential diagnosis of, TSH stimulation test in, 6:451-452
 - hand in, 6:665
 - in infancy and childhood, 4:1151-1152
 - iodide-organification defect and, 6:448
 - low basal metabolism and, 4:1127
 - from radioiodine treatment, 6:500-502
 - treatment of, 6:465-473
- Hypovolemia, 4:285-288, 291-293
- Hypoxia, 6:12-13, 15-25, 239, 240, 244, 350
- arterial, with obesity, 4:1162-1163
 - defining extent of, 6:22-25
 - signs and effects of, 6:18-22
- Hysterectomy in abruptio placentae, 5:409
- Illness
- denial of, 6:721, 722-723
 - feelings of loneliness in, 6:889-892
 - felt to be punishment, 6:887-889
 - psychological disturbances in, 6:732-745, 866-869
- See also Disease
- Immunity problems of kidney transplantation, 6:952-964
- Immunizations, 5:879-880
- allergic and immunologic reactions to, 5:881-883
 - direct induction of disease by, 5:881
 - in pregnancy, 5:881
 - reactions to individual vaccines, 5:883-889
- Impotence in diabetic, 4:54-55
- Indandione, hemorrhagic complications from, 5:372-374
- Indomethacin therapy for pain, 5:1110
- Infantile spasms, 6:1218
- Infants
- body water in
 - amount, 5:617, 684-685

- requirements, 5:685-688
 fluid and electrolyte disturbances in, 5:684-697
See also Newborn
- Infarction, myocardial, *see* Myocardial infarction
- Infection
 acute, in febrile convulsions, 6:1186
 airway obstruction and, 4:1173
 burn wounds, control of, 4:1275-1277
 urticaria with, 5:830
- Inflammatory neuropathies, 5:1263-1266
- INH, *see* Isoniazid
- Injury, traumatic, *see* Traumatic injury
- Insect sting reactions, 5:814-824
 characteristics of, 5:814-816
 urticaria, 5:815, 830
 fatalities from, 5:814, 815-816
 hypersensitization against, 5:790, 815, 818-820
 patient's education in cases of, 5:815, 821-822
 treatment of, 5:816-818, 822-823
- Insecticide as poison, 4:626-632
- Inspection, 6:665-666
- Insulin
 daily secretion of, by pancreatic beta cells, 4:16
 human, 4:18-19
 idiopathic chronic resistance to, 4:16-24, 87
 lipodystrophy and, 4:83
 in obese diabetic, 4:1190
 pork, 4:18
 requirement for, in diabetic with infection, 4:27
 sensitivity to, of adipose tissue, 4:1086
- Insulinoma, 4:1001
- Intensive care units, psychotic reactions to, 6:743
- Intermediate-acting block therapy, 5:1185
- Intermittent positive-pressure breathing (I.P.P.B.), 6:92-102, 351
 aerosol with, 6:366, 368
 in emphysema, 6:335-339, 341-342
 in status asthmaticus, 6:311-317
- Interstitial fluids, 5:620-621
- Intertrigo, candida, 4:80-81
- Interviewing, 6:656-687, 778-781
 focusing verbal exchange in, 6:677-679
 goals of, in initial interview, 6:672-673
 indiscretions in, 6:674-677
 inspection in, 6:665-666
 process of, 6:667-674
 subsequent, 6:679-681
See also History taking
- Intracranial pressure increased
 in pyogenic meningitis, 4:900-901, 924-925
 in tuberculous meningitis, 4:944-945
- Intracranial surgery for neuralgia, 5:1274-1275
- Intrathecal therapy
 in meningococcal meningitis, 4:935-936
 in neonatal meningitis, 4:914
 in pyogenic meningitis, 4:927-928
- Intravenous route for postoperative patient, 5:1157-1158
- Ischemia, 4:350-351, 386, 387, 388
 with neuritis, 4:358, 387
 splanchnic, regional-block therapy for, 5:1182
 with ulceration, 4:377-378
- Ischemic neuropathies, *see* Vascular neuropathies
- Islet cell adenoma, 4:1001
- Isoniazid, 5:850
 desensitization to, 5:809
- Isoniazid-induced neuropathy, 5:1237-1238
 INH withdrawal in, 5:1238
- Isoniazid therapy
 in children, 4:183, 184, 187
 for drug-induced neuropathy, 5:1239
 for tuberculous meningitis, 4:939, 941-942, 949
 for tuberculous pericarditis, 4:143
- Isoproterenol
 for arterial disorders of the extremities, 4:385
 for pyogenic meningitis, 4:903-909
 for shock, 4:243, 246, 250, 252, 271, 274, 283, 284-285, 291, 314-315, 327, 337

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1388 / Cumulative Index

Jaundice in drug allergy, 5:805
Jewish patients, 6:893-894

Joints

contractures of, 5:907
degenerative disease of, 5:1019-1020
measurement of mobility of, 5:895
in stroke patient, 5:978, 980
in peripheral nerve syndromes,
5:998-999
protection of, in neuropathic patient,
5:1213

Karyotype, genetic, 4:838, 839

Ketonuria as drug reaction, 5:1103

Kidney stones

analysis of, 4:466, 477-479
calcium, 4:467-470
hyperparathyroidism and, 4:489-
492, 497
treatment, 4:472, 480-481, 483-
485, 494-501, 526
causes of, 4:512
cystine, 4:470, 473, 539, 540, 543,
545-548
treatment, 4:473, 540, 543, 545-
548, 551
See also Cystinuria
diagnosis of, 4:465-471, 477-479
hypercalcemia and, 4:468-469
hypercalciuria and, 4:468-470
hyperparathyroidism and, 4:489-492,
497
idiopathic, 4:500-502
with infection, 4:497, 502-503, 505-
512

prognosis, 4:513
lithiasis and, *see* Lithiasis, renal
matrix, 4:465, 471, 494-495
mixtures of, 4:473
oxalate, 4:522-529; *see also* Oxaluria
recurrence of, 4:464, 496, 501-503
renal tubular acidosis and, 4:519
treatment of
aims, 4:473-474
allopurinol, 4:532-536
oxalate reduction, 4:526-529
penicillamine, 4:543-547
phosphates (inorganic), 4:494-503
special diet, 4:480-481, 482, 483-
485
triple-phosphate, 4:505-514
uric-acid, 4:470, 472-473, 531-536
xanthine, 4:471, 536-537

Kidneys

in acid-base regulatory system,
5:638-639, 650
acidosis from, 5:642
artificial, 5:626; 6:923

types, 6:1057-1058

See also Dialysis

effect of continuous pain of, 5:1086
hypoxia effects on, 6:21-22
morphine distribution to, 5:1139
relief of pain in, 5:1204
solitary, renal failure and, 5:933
transplantation of, 5:626; 6:923,
952-983

See also Nephrotic syndromes; Renal
disease; Renal failure; Uremia
Kwashiorkor, 4:1029, 1036
Kyphoscoliosis, respiratory failure with,
6:38-39, 112

Labial herpes, recurrent, 4:556, 558-
559, 562-564

Labor

analgesic effect on course of, 5:1169
prevention of dehydration in, 5:720

Labor pain

analgesia for, 5:1165-1171
control of, 5:1088, 1095
as function of attitude, 5:1165-1166

Labyrinth and paroxysmal vertigo,
6:1293-1295

Lactic acidemia, 6:270-271

Lactic acidosis, 5:644-645

treatment of, 5:651

Laparotomy, respiratory failure after,
6:36-37

Laryngeotracheobronchitis, 6:366

Larynx, obstruction of

anaphylactic, 5:787, 789

as complication of bleeding, 5:56

Lateral femoral cutaneous neuropathy,
5:1223

Laurence-Moon-Biedl syndrome in
childhood obesity, 4:1152-
1153

Lavage, gastric, 4:602-605

for poisoning, 4:628, 631, 637, 638,
674-675, 704-706

Lead as poison, 4:710-728

Lead neuropathy, 5:1242-1243

prevention of, 5:1243

Leg pain

neuropathic, 5:1223, 1224, 1227
regional-block therapy for, 5:1183

Leishmaniasis, visceral, 6:155-156

Leprosy

cutaneous anesthesia in, 5:1086
neuropathy with, 5:1266

Leukemia

pulmonary insufficiency in, 6:111
thrombocytopenia with, 5:435-436

Levallorphan, 5:1146, 1149-1150
for labor pain, 5:1168

Cumulative Index / 1389

- Levarterenol in shock, 4:250-251, 306
 Levorphanol, 5:1146
 Light urticaria, 5:834
 Lipid metabolism, disorders of, 4:1011
 mental retardation with, 4:1012-1018
 neuropathies, 5:1211, 1232-1233
 Lipoproteins, 6:1313-1316
 major classes of, 6:1329-1332
 Lithiasis, renal
 causes of, 4:512
 with hyperparathyroidism, 4:497
 with infection, 4:505-514
 See also Kidney stones
 Liver
 barbiturate action on, 4:683
 damaged, morphine dosage with, 5:1141
 drug metabolism in, 5:1139, 1142, 1148
 effect of salicylates on, 5:1103
 homotransplantation of, 6:140
 Liver diseases
 bleeding in, 5:368-371
 cirrhosis, primary biliary, 6:1355-1357
 in drug allergy, 5:805
 gallstone formation and, 5:488
 hereditary and neonatal, 6:1352-1354
 lack of information about, 6:110
 miscellaneous forms of, 6:1357-1358
 obstructive, 6:1325, 1354-1355
 parasite, 6:121, 153-164
 See also specific diseases
 Loeffler's syndrome, 6:105-106
 Long-acting block therapy, 5:1185-1191
 background of, 5:1185-1186
 intrathecal use of, 5:1188-1191
 managing complications of, 5:1186
 peripheral use of, 5:1186-1188
 Long thoracic neuropathy, 5:1217
 Love and disease, 6:654
 Low back pain, 5:1022-1035
 mechanics of, 5:1022-1028
 treatment of, 5:1028-1035
 Lower extremity neuropathies, 5:1221-1225
 Lower plexus root injury neuropathy, 5:1215-1216
 LSD, 6:715-716, 742, 804
 Lues and associated pericarditis, 4:151
 Lumbar puncture, 4:880-881, 981-982
 Lumbrosacral serves in regional-block therapy, 5:1180-1181
 Lungs
 edema of, 6:42
 aerosol therapy for, 6:370
 renal failure and, 6:942-943
 fluid therapy and, 4:1278
 radiation damage of, treatment of, 6:110
 surgical extirpation of, 6:42
 cor pulmonale and, 6:251
 tests of function of, 6:233-239
 in cor pulmonale, 6:257-258
 See also Ventilation; specific diseases, entries beginning with Respiratory
 Lupus erythematosus (LE), 5:379, 432
 arthritis with, 5:1011
 disseminated, and associated pericarditis, 4:155
 drug-induced, 5:805
 respiratory ventilatory impairment in, 6:104
 urticaria with, 5:830
 Lupus nephrotic syndrome, 6:1008-1009
 Lymphadenitis
 antibiotic therapy in, 6:391-395
 endolymphatic therapy in, 6:379
 Lymphangiosarcoma, treatment of, 6:418-419
 Lymphangitic carcinoma, 6:111
 Lymphedema, 6:373-421
 classification of, 6:373, 375-376, 398-400
 lymphangiographic evaluation in, 6:373, 375-379
 treatment of
 endolymphatic therapy, 6:379
 of idiopathic lymphedema, 6:381-383
 of postmastectomy lymphedema, 6:396-412
 of secondary lymphedema, 6:384-390
 surgical treatment, 6:413-418
 Lymphoma, treatment of, 6:111

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1390 / Cumulative Index

- Macroglobulinemia, 5:35, 455-458
- Magnesium
 - basic considerations for, 5:669-670
 - deficiency of, 5:670-672
 - excess of, 5:672-674
 - potassium and, 5:663
- Main's syndrome, 6:721, 724-727
- Malignant tumors, surgical treatment
 - of, 5:1202-1203
 - head tumors, 5:1205-1206
- Malnutrition and pseudoretardation, 4:756-758
- Manic depressive psychosis, lithium
 - carbohydrate in, 6:804
- Mannitol
 - in burn therapy, 4:1224
 - for shock, 4:268-269, 293
- Maple syrup urine disease, 4:1030
- Marfan's syndrome, hand in, 6:666
- Marihuana, 6:715, 805
- Massage, 5:912-913
- Mastectomy, lymphedema after, 6:396-412
- Mastocytosis, systemic, 5:784
- Matrix kidney stones, 4:471, 494-495
- Maturation, delayed, and mental retardation, 4:754
- Maturation index, 5:559
- Maximal voluntary ventilation test, 6:235-236
- Measles vaccine, complications from, 5:885-886
- Medial plantar neuropathy, 5:1224
- Median neuropathy, 5:1220-1221, 1234
- "Medic-Alert" identification, 5:790, 809-810
- Medication for postoperative patient
 - choice of, 5:1160-1162
 - dosage of, patient's age and, 5:1159-1160
 - evaluation of patient before, 5:1156-1157
 - route of admission of, 5:1157-1158
 - timing of, 5:1158
 - See also* Analgesic therapy, for postoperative pain
- Mediterranean fever, 4:156
- Medulla, effect of morphine on, 5:1139
- Mefenamic acid therapy for pain, 5:1109-1110
- Meiosis, 4:838, 841
- Meniere's disease, 6:553-567, 605-606
- Meninges, involvement of, by cancer, 4:854
- Meningitis
 - acromegaly after treatment of, 4:168
 - acute syphilitic, 4:894
 - autonomic changes in, 4:972-974
 - brain abscess and, 4:978
 - cardiac changes in, 4:973
 - cerebral edema in, 4:935, 968-971
 - CSF in, 4:879-896, 976
 - convulsions and, 4:901, 902, 943-944, 971-972
 - cryptococcus, 4:886, 894
 - amphotericin B therapy, 4:956, 957, 958
 - fistula and, 4:978-979
 - focal neurologic dysfunction and, 4:979-982
 - gastrointestinal changes in, 4:974
 - hyperglycemia in, 4:974-975
 - hyperthermia in, 4:974
 - meningococcal, 4:929-938
 - metabolic disturbances in, 4:975
 - mycotic, 4:951-960
 - neonatal, 4:909-915
 - overhydration in, 4:975
 - peripheral vascular collapse in, 4:973
 - purulent, 4:885, 887, 891-893
 - pyogenic
 - in adults, 4:918-928, 946, 963
 - in infants and children, 4:898-915
 - respiratory disorder in, 4:973-974
 - sequelae of, 4:968-983
 - subdural effusion and, 4:906-907, 977-978
 - tuberculous, 4:939-950
 - viral, 4:961-967
- Meningococcal infection, 4:929-938
 - clinical types of, 4:930-931
 - See also* specific infections
- Meningococcemia, chronic, 4:931
- Menopause
 - atherosclerosis and, 5:581-586
 - psychodynamics of, 5:588-590
 - symptoms of, 5:546-548
 - treatment of, 5:545-563
 - by hormonal therapy, 5:545-546, 550-562, 590-595
 - by nonhormonal therapy, 5:550
 - by psychiatric therapy, 5:554, 561, 587-595
 - See also* Osteoporosis—menopausal
- Menorrhagia, hemorrhagic defects and, 5:57-58
- Menstrual cycle, behavior patterns and, 6:650
- Meperidine (Demerol), 5:1143-1145
 - dependence on, 5:1128, 1132, 1176
 - for treatment of pain
 - labor pain, 5:1166-1167, 1168, 1171
 - postoperative pain, 5:1154
- Mephentermine for shock, 4:243, 246, 250, 295, 304, 315

- Mephobarbital**
dosage and preparation of, 6:1228
epilepsy and, 6:1223
side-effects of, 6:1226-1227
- Mercury neuropathy**, 5:1246
- Mercury as poison**, 4:734-739
- Mescaline**, 6:715, 742, 804-805
- Mesencephalic tractotomy to relieve pain**, 5:1201
- Metabolic neuropathies**, 5:1226-1235
- Metachromatic leucodystrophy**, 5:1233
- Metaraminol for shock**, 4:249-251, 290, 306-307
- Metadone**, 5:1148-1149
drug dependence and, 5:1132, 1133
for postoperative pain, 5:1176
- Methemoglobinemia**
hereditary, 4:1043-1044
from phenacetin, 5:1105
- Methionine malabsorption**, 4:1033
- Methotrimeprazine therapy for pain**
labor pain, 5:1169, 1171
postoperative pain, 5:1176
postpartum pain, 5:1173
- Methoxamine for shock**, 4:246, 251-252, 294, 306
- Methsuximide**
dosage and preparation of, 6:1228
epilepsy and, 6:1225
side-effects of, 6:1226-1227
- Methyl alcohol (Methanol) poisoning**, 5:646, 652
- Methyl cellulose for appetite reduction**, 4:1141-1142
- Methysergide for neuralgia**, 5:1276
- Micelles**, 5:484-487
- Middle ear and paroxysmal vertigo**, 6:1292-1293
- Migrain, vertigo in**, 6:591-593
- Migrainous neuralgia**, 5:1275-1276
- Milestones in life and changes in health**, 6:647-649
- Ministers, assistance to physician by**, 6:885-899
- Minot-von Willebrand syndrome, prolonged bleeding with**, 5:1102
- Miosis from morphine**, 5:1140
- Mipaflox neuropathy**, 5:1245-1246
symptomatic and preventive treatment of, 5:1245-1246
- Mitosis**, 4:838
- Monoamine oxidase inhibitors, in Parkinson's disease**, 5:293, 297-298
- Mononeuropathy, metabolic**, 5:1228-1229, 1234
- Mononucleosis, infectious**
arthralgia with, 6:1149
with pericarditis, 4:151
- Morphinan derivatives**, 5:1145-1146
- Morphine**, 5:1137-1141
absorption, dosage and metabolism of, 5:1138-1139
activity and structure relationships of, 5:1137-1138
contraindicated in burn patients, 4:1198
dependence on, 5:1123, 1128-1129
for labor pain, 5:1167, 1171
mechanism of analgesia and addiction to, 5:1139
pharmacologic actions of, 5:1139-1141
for postoperative pain, 5:1156, 1159, 1160-1161
of gynecologic patients, 5:1175-1177
tolerance toward, 5:1141
- Morquio's syndrome**, 5:237-238
- Mosaicism**, 4:841
- "Mourning,"** 5:896
- Mucopolysaccharidosis**, 4:1005-1006
- Multiple sclerosis, vertigo from**, 6:579-585
- Mumps**
arthritis in, 6:1147
vaccine, complications from, 5:886
- "Munchausen's Syndrome,"** 6:705
- Muscle relaxants in treatment of pain**, 5:1114-1116, 1119
- Muscles**
atrophy of, 5:906-907
hypoxia effects on, 6:21
in neuropathy
Bell's palsy, 5:1280-1281, 1283
effect of neuropathy, 5:1216, 1217, 1220-1223, 1229, 1240, 1244, 1245, 1253
muscle-training exercises, 5:1237
in peripheral nerve syndromes, 5:998-999

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1392 / Cumulative Index

- skeletal, morphine distribution to, 5:1139
- testing of strength of, 5:895-896
- in stroke patients, 5:977-978
- Muscular dystrophy
 - respiratory failure in, 6:33
 - See also* Dystrophy
- Muskel neuropathy, 5:1247
- Myalgia, treatment of pain of, 5:1095
- Myasthenia gravis
 - acidosis from, 5:653
 - respiratory failure in, 6:33, 34
- Mycotic arthritis, 6:1124-1128
- Mydriasis from mepheridine, 5:1144
- Myeloma, multiple, mypercalcemia due to, 5:682
- Myelopathy, *see* Spinal cord injuries
- Myeloproliferative syndromes, bleeding complications in, 5:380-381
- Myocardial infarction
 - acute
 - differentiated from acute pericarditis, 4:147-148
 - pericarditis of, 4:176-179
 - shock and, 4:299-318
 - mepheridine for, 5:1144
 - treatment of pain of, 5:1095
 - vertigo from, 6:572
 - Myocarditis for immunization, 5:884
 - Myocardium, emetine effect on, 4:151
 - Myoclonic seizures, 6:1219-1220
 - Myopathic-myasthenic syndrome, neuropathy with, 5:1271
- Myopathies
 - inflammatory, 5:1045
 - primary, definition of, 5:1036
 - rehabilitative goals in, 5:1037
- Myxedema
 - causing cholesterol pericarditis, 4:158
 - coma, 6:466-469
 - with drug-induced neuropathy, 5:1240
 - median neuropathy with, 5:1220
 - as metabolic neuropathy, 5:1232
- Nalorphine, 5:1138, 1149
- Narcolepsy, 6:1263-1264
- associated symptoms, treatment of, 6:1271-1272
- in children, treatment of, 6:1272
- decreased wakefulness, treatment of, 6:1264-1267
- limitations, 6:1272-1273
- nocturnal sleep, inadequate, treatment of, 6:1268
- pupillogram, 6:1269-1271
- Narcotic addiction, 6:711-713
- See also* Drug addiction
- Narcotic analgesic therapy
 - for pain
 - analgesic combinations, 5:1119, 1129
 - labor pain, 5:1166-1168
 - neuropathic pain, 5:1239
 - postoperative pain, 5:1158, 1175
 - "weak" drugs, 5:1110-1114
 - See also* Opiate dependence; Opiates
- Narcotic antagonists, 5:1149-1150
- Nasal occlusion, antihistamines for, 5:840-841, 842
- Neck
 - burns of, 4:1311
 - pain of, 5:1183, 1200
 - rigidity of, in Parkinson's disease, 5:262-263, 279-280
- Necrobiosis lipodica, 4:73-74
- Necrosis
 - cortical, in meningitis, 4:979
 - of feet, in diabetes, 4:109-113
 - renal papillary, in diabetic, 4:41
- Neoplasms associated with pericarditis, 4:159-160
- Neoplastic (carcinomatous) neuro-myopathies, 5:1270-1271
- Nephritis
 - from immunization, 5:884
 - "phenacetin," 5:1106
- Nephropathy
 - analgesic, 5:1118, 1119
 - diabetic
 - diagnostic tests, 4:39-40
 - hypophyseal stalk section, 4:41
 - pathology, 4:31-32
 - prognosis, 4:42
 - renal arteriosclerosis, 4:142
 - renal biopsy, 4:31
 - renal papillary necrosis and, 4:41
 - sulphonylurea drugs, 4:31
 - treatment, 4:31-42
 - nonspecific, from phenacetin, 5:1106
 - See also* Renal failure
- Nephrotic syndromes
 - idiopathic, 6:1000-1008
 - lupus, 6:1008-1009
- Nerve decompression in Bell's palsy, 5:1282
- Nerve fiber transmission of pain, 5:1084-1085
- Nervous system, *see* Central nervous system; Degenerative neurologic disease; Peripheral nerve syndromes; *specific nervous disorders*
- Neuralgia, 5:1272-1277
- defined, 5:1211-1212

- regional-block therapy for, 5:1184, 1185, 1274
- specific therapy for, 5:1088
- surgical therapy for, 5:1273-1274
- neuralgia of head and neck, 5:1204-1205
- secondary neuralgia, 5:1204
- Neuritis
 - defined, 5:1211
 - See also Neuropathies; Polyneuritis
- Neurogenic vesical dysfunction, 4:52-54
- Neurolytic drugs, *see* Regional-block therapy
- Neuroma
 - acoustic, vertigo and, 6:576-579, 613
 - surgical therapy for, 5:1203-1204, 1224
 - from surgery, 5:1199
- Neuropathies
 - case histories of, 5:1218-1222, 1224, 1257
 - general care of, 5:1212-1214
 - surgical treatment of, 5:1216, 1220, 1223, 1224, 1225, 1232, 1273-1275
 - varieties of, 5:1215-1284; *see also specific neuropathies*
 - See also Neuralgia; Neuritis
- Neurophysiology, 5:1197-1199
- modality-specific, 5:1197-1198
- of structures in emotional response, 5:1198-1199
- Neurosis
 - differential diagnosis between psychosis and, 6:877-879
 - sociopathy compared to, 6:709
- Neurosurgical therapy, 5:1197-1208
 - for Bell's palsy, 5:1282-1283
 - for head and neck pain, 5:1204-1206
 - for neuropathies, 5:1216, 1220, 1223, 1224, 1225, 1232, 1273-1275
 - procedures for, 5:1199-1204
- Newborn
 - decreased conjugation of bilirubin in, 4:996-997
 - of diabetic mother, 4:993-994
 - effect of analgesics on, 5:1144, 1169-1170
 - exchange transfusion for, 4:995, 996
 - hemolytic disease of, 4:996
 - hyperbilirubinemia in, 4:995-997
 - meningitis in, 4:909-915
 - metabolic and endocrine disorders in, 4:988-997
 - See also Infants
- Nicotinamide therapy for deficiency neuropathy, 5:1255-1257
- Nitrofurantoin-(furadantin) induced neuropathy, 5:1238-1239
- Nitrogen mustard in therapy for chronic insulin resistance, 4:23
- Nocardiosis, 6:1124-1128
- Normosol-R for burn therapy, 4:1221, 1222, 1224
- Nutmeg, 6:715, 742
- Nystagmus, vertigo and, 6:580, 599-601, 603
- Obesity
 - acidosis from, 5:653
 - adipose tissue metabolism and, 4:1083-1094
 - in adolescence, 4:1116-1117
 - anthropologic characteristics in, 4:1105-1106
 - appetite suppressants in, 4:1172
 - cardiopulmonary disorders in, 4:1162-1179
 - cardiopulmonary syndrome of, 4:1164-1165
 - cardiorespiratory function in, 4:1162-1163
 - CNS in relationship to development of, 4:1117-1119
 - in childhood, 4:1116, 1146-1160
 - criteria for, 4:1097
 - height-weight tables, 4:1107
 - table of standards, 4:1098, 1099
 - definition of, 4:1083, 1096
 - diabetes and, 4:1181-1190
 - basic therapy, 4:90, 1181-1190
 - diabetes mellitus and, 4:1106-1107
 - diagnosis of, 4:1127-1129
 - dietary treatment of, 4:1125-1163
 - drug therapy in, 4:1138-1144
 - evaluation of patient with, 4:1131-1132
 - experimental, 4:1090-1092
 - frequency of, 4:1098-1100

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
 Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
 Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1394 / Cumulative Index

- gallbladder disease and, 5:496, 497
- general principles of treatment of, 4:1129
- genetic, 4:1126
 - difficulties in estimating genetic parameters, 4:1100
 - in experimental animals, 4:1091-1092, 1100, 1101
 - familial aggregation, 4:1101-1102
 - racial or ethnic comparisons, 4:1103-1104
 - sex ratios, 4:1104-1105
 - twin studies, 4:1102-1103
- hypoglycemia and, 4:1128
- hypothyroidism and, 4:1127
- incidence of, and behavior abnormality in, 4:1112-1113
- measurement of triceps skinfold thickness in, 4:1097-1098, 1107
- metabolic abnormalities in, 4:1093-1094, 1126
- overweight condition vs., 4:1096-1097, 1147
- pathophysiology of, 4:1165-1168
- physical activity and, 4:1127
- problems in treatment of, 4:1120-1122
- psychiatric aspects of, 4:1111-1123
 - from reduced caloric expenditure, 4:1126-1127
- regulatory, 4:1126
- relationship of, to addiction, 4:1119-1120
- respiratory failure in, 6:34-35, 102
- schizophrenia and, 4:1113-1116
- steroids causing, 4:1126
- tumors affecting food-control center in, 4:1126, 1128
- Obstetric analgesia, *see* Analgesic therapy—for obstetric and gynecologic patients
- "Obstetric shock," 5:407
- Obstructive disease, *see* Respiratory failure—obstructive
- Occlusion
 - arterial
 - acute, 4:411-415
 - vasodilators for, 4:370-371, 375, 376-378
 - See also* Arteriosclerosis, occlusive
 - vascular, neuropathy with, 5:1267-1268
- Occlusive dressings in burn wounds, 4:1251-1253
- Older persons, clergymen and needs of, 6:892-893
- Oliguria in shock, 4:294, 296-297
- Opiate dependence
 - narcotic antagonists and, 5:1149
 - relief of pain and, 5:1121-1135
- Opiates, varieties of, 5:1136-1143; *see also specific opiates*
- Opioids, varieties of, 5:1143-1149
- Oral contraceptives, suppression of dysmenorrhea by, 5:587
- Oral hypoglycemic drugs in obese diabetic, 4:1187-1190
- Orthopedic management in hereditary disorders of blood coagulation, 5:84-92
- Orthoses, 5:901-902
 - definition of, 5:900
- Osteitis fibrosa cystica, 6:1048
- Osteoarthritic knee, rehabilitation of, 5:1020
- Osteogenesis imperfecta, 5:32, 447-448
- Osteomalacia, 6:1048
 - renal tubular acidosis and, 4:519
- Osteomyelitis
 - from immunization, 5:884
 - septic arthritis in children with, 6:1111-1112, 1112-1113
- Osteoporosis
 - corticosteroids and, 5:849
 - from disuse, 5:907
 - menopausal
 - defined, 5:571
 - described, 5:680-681
 - evaluation of, 5:571-573, 578-579
 - theory of hormone deficiency, 5:573-576
 - treatment, 5:548, 553-554, 571-580, 681
 - in primary biliary cirrhosis, 6:212
- Otorrhea and meningitis, 4:978
- Ovaries, growth-affecting diseases of, 5:205-217
- Oxalate
 - in kidney stones, 4:522-529
 - metabolism of, 4:524-525
 - reduction of, 4:526-528
- Oxaluria, 4:522-529
- Oxidation-reduction metabolic disorder, 4:1043-1044
- Oxygen, consumption of, in obesity, 4:1163
- Oxygen therapy
 - for burns, 4:1270-1272
 - for hypoxia, 4:1171-1172; *see also* Hypoxia
 - for obesity, 4:1171-1172
- Oxymorphone, 5:1138, 1142
 - for postoperative pain, 5:1142, 1176
- Oxyphenbutazone therapy for pain, 5:1108-1109

- Pain, 5:1083-1210
analgesic therapy for, 5:1094-1153, 1164-1179
in arteriosclerosis obliterans, 4:95
from burns, relief of, 4:1197-1198
clinical aspects and necessity for relief of, 5:1086
concepts of, 5:1083-1085
control of, 5:1086-1091
cancer patient's pain, 5:1089-1091, 1125
in coronary artery disease with diabetes, 4:97
nonsurgical therapy for, 5:1197-1208
opiate dependence and, *see* Opiate dependence—relief of pain and perception of, 5:1084-1085, 1199
regional-block therapy for, 5:1180-1196
rest, in occlusive arterial disease, 4:113
See also specific types of pain
- Pain-prone individuals
as addicts, 5:1125-1126
management of, 5:1128
recognition of, 5:1127
- Palsy
Bell's, *see* Bell's palsy
from brachial plexus injury, 5:1215
facial and meningitis, 4:979-980
"Saturday Night," 5:1217-1218
with toxic neuropathy, 5:1243
- Pancreas, insulin-secreting adenomas of, 5:1230
- Pancreatitis
acute
control of pain, 5:1087
oliguria with, 4:445
regional-block therapy, 5:1182
benign, regional-block therapy for, 5:1184
biliary tract disease with, 4:441, 443
after cholecystectomy, 5:529-531
cholecystitis with, 5:521
chronic relapsing, control of pain of, 5:1088, 1089
gallstones and, 5:496, 497
magnesium deficiency with, 5:671
- Para-aminosalicylic acid therapy for tuberculous pericarditis, 4:143-144
- Paragranuloma, *see* Hodgkin's disease
- Parahemophilia
diagnosis of, 5:22
surgical care in, 5:77-78
therapy for, 5:51
- Paraldehyde poisoning, 5:646
- Paralysis with neuropathy, 5:1244-1247, 1261; *see also* Bell's palsy
- Paramethadione
dosage and preparation of, 6:1228
epilepsy and, 6:1225
side-effects of, 6:1226-1227
- Parasitic diseases of the liver, 6:121, 153-164
- Parasitic infestation, urticaria with, 5:830
- Parathyroid adenoma, stone analysis in, 4:479
- Parathyroid glands in renal failure, 6:1047-1048
- Parenchymal disease, pulmonary, 6:32, 33, 40-42
- Paresthesias
"acroparesthesias," 5:1211
as drug side-effect, 5:1296
neuropathic, 5:1217, 1219, 1220, 1223, 1227, 1246, 1253
- Parkinson's disease
analysis of disability in, 5:257-282
diagnosis of, 5:258-264
medical treatment of, 5:255-256, 283-300
physical therapy and exercise in, 5:288-289
psychotherapy in, 5:299
rehabilitation in, 5:1003-1009
self-care in, 5:277-278, 281-282
surgical treatment of, 5:256, 301-315
See also specific symptoms
- Paronychium, chronic inflammation of, in diabetic, 4:80
- Patients
acutely ill, psychological disturbances of, 6:732-745
dying
clergymen and, 6:897-898
management of, 6:746-759

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1396 / Cumulative Index

- religious concerns of, 6:893-894
- See also* Physician-patient relationship; Special patients
- Pectus excavatum, 6:39-40
- Pellagra, 4:1038
- Pelvic pain
 - postoperative, 5:1174
 - regional-block therapy for, 5:1180
- Penicillamine
 - chemical structure of, 4:544
 - for cystinuria, 4:543, 545-547
 - for lead neuropathy, 5:1243
 - for poisoning, 4:737-739
 - in Wilson's disease, 5:322, 323-327, 329
- Penicillin
 - annual deaths from reaction to, 5:782, 792
 - dairy products contaminated with, 5:810
 - skin testing for allergy to, 5:796, 800, 809
- Penicillin therapy
 - hypersensitivity to, and acute pericarditis, 4:152
 - in meningococcal meningitis, 4:934
 - in purulent pericarditis, 4:139-141
 - in pyogenic meningitis, 4:904-905, 920-922
 - in rheumatic pericarditis of childhood, 4:193
- Pentazocine, 5:1147-1148, 1149
 - for relief of pain, 5:1124, 1130, 1131-1133
 - labor pain, 5:1171
 - postoperative pain, 5:1176
 - postpartum pain, 5:1173-1174
- Peptic ulcers
 - control of pain, 5:1087
 - corticosteroids in, 5:848-849
 - as drug side-effect, 5:1109, 1269
 - occult blood loss with, 5:1102
 - in primary biliary cirrhosis, 6:212
 - supervision of nonpsychiatric physician in case of, 6:850-852
- Periadenitis apthae, 4:564, 567-570
- Periarthritis nodosa, 6:106
- Pericardial fluid, 4:126
 - abnormal collections of, 4:212-214, 217-219
- See also* Cardiac tamponade
- Pericardiectomy
 - in constrictive pericarditis, 4:221-224
 - in tuberculous pericarditis, 4:145
- Pericardiocentesis, 4:148, 174-175, 177, 188-189
- Pericarditis
 - acute, 4:126-129, 147-148
 - idiopathic, in children, 4:89-193
 - of acute myocardial infarction, 4:176-179
 - allergic, 4:152-153
 - amebic, 4:150-151
 - chemical and metabolic causes of, 4:157-159
 - in children, treatment of, 4:182-195
 - cholesterol as cause of, 4:158
 - chronic constrictive, 4:131-134, 147, 220-221
 - nonsurgical treatment, 4:166-168
 - prevention, 4:163-164
 - surgical treatment, 4:162, 165-166, 167, 221-224
 - treatment, 4:132-133, 162-169
 - effusion in, *see* Effusions—pericardial
 - fungal, 4:149-150
 - gout and, 4:159
 - infectious, 4:135-145
 - miliary gummatous, 4:151
 - neoplastic, 4:159-160
 - nonspecific, 4:135-138
 - pain in, 4:126-127, 136, 147
 - purulent (bacterial), 4:138-141
 - causes, 4:149-151
 - in children, 4:182-189
 - identifiable bacteria in, 4:187
 - primary lesions, 4:138-139
 - therapy, 4:139-141, 187
 - relapsing, 4:219-220
 - in renal failure, 6:1052-1053
 - rheumatic, in children, 4:193-194
 - rheumatoid disease of childhood and, 4:194-195
 - systemic disease with, 4:147-160
 - traumatic, in children, 4:195
 - tuberculous, 4:141-145
 - in children, 4:183-189
 - uremic, 4:157-158
- Pericardium
 - absence of, 4:126, 206-207, 208
 - congenital lesions of, 4:206-209
 - cysts of, 4:209
 - diseases of, 4:125, 205-206
 - diverticula of, 4:208-209
 - effect of cholesterol on, 4:158
 - fluid in, 4:126
 - abnormal collection, 4:212-219
 - see also* Pericardial fluid; Pericardiocentesis
 - function of, 4:125-126, 207-208
 - inflammation of, *see* Pericarditis
 - open drainage of, 4:219
 - surgical excision of, 4:158
 - tumors of, 4:209-212
- Perineal pain
 - postoperative, 5:1174, 1175, 1177

- regional-block therapy for, 5:1184
 Peripheral nerve syndromes, 5:996-1002
 etiology of, 5:996
 management of, 5:997-1002
 prevention of, 5:997
 Peripheral neurectomy to relieve pain, 5:1199
 Perleche in diabetic, 4:81-82
 Pernio, 4:380
 Peroneal palsy, cause of, 5:1223
 Pertussis immunization, complications from, 5:885
 Petechiae in meningococcal meningitis, 4:932, 933-934
 Petit mal seizures, 6:1219
 drugs effective against, 6:1224-1228
 Petroleum distillates as poison, 4:697-708
 Phantom pain
 after amputation, 4:436-437
 surgical relief of, 5:1203-1204
 Phelantin and epilepsy, 6:1224
 Phenacetine
 addiction, 6:714
 therapy for pain, 5:1105-1106
 See also A.P.C. therapy for pain
 Phenazocine, 5:1147, 1148
 Phenformin in maturity-onset diabetes in obese, 4:1187-1189
 Phenobarbital, 6:1187
 dosage and preparation of, 6:1228
 effective against grand mal and focal-motor seizures, 6:1222-1223
 side-effects of, 6:1126
 Phenol blocks
 in degenerative neurologic disease, 5:1006
 in spinal cord injuries, 5:965-968
 Phenothiazines
 in Huntington's disease, 5:336-340
 for labor pain, 5:1169
 in Parkinson's disease, 5:293, 296
 in Sydenham's chorea, 5:353-354
 See also Methotrimeprazine
 Phenotolamine in shock, 4:243, 246, 248-250
 Phenotype, 4:841
 Phenylbutazone therapy for pain, 5:1108-1109, 1118
 Phenylephrine for shock, 4:246, 290
 Phenylpyrazole therapy for pain, 5:1107-1109
 Phenylramidol therapy for pain, 5:1116
 Phosphate
 inorganic, for renal calculi, 4:494-503
 in treatment of metabolic acidosis, 5:650
 Phospholipids, 6:1309-1310
 Photocoagulation in diabetic retinopathy, 4:69-70
 Photosensitization in drug allergy, 5:803
 Physician-patient relationship, 6:614, 646-647
 with dying patients, 6:752-758
 supervision for nonpsychiatric physician in, 6:842-856
 teacher-student relationship vs., 6:658-660
 See also History taking; Psychotherapy
 Physiotherapy in reduction of airway obstruction, 4:1173-1174
 Pia-glial membrane, 4:877
 Pickwickian syndrome, 4:1164
 "PIE" syndrome, 4:153
 Pimindine, 5:1144, 1145
 Piperidine derivatives, varieties of, 5:1143-1145
 Piperidyl compounds in Parkinson's disease, 5:293-295
 Pituitary
 growth-affecting diseases of, 5:139-152
 TSH regulation by, 6:451
 pK of barbiturates, 4:679-682
 Placebo response
 positive, opiate dependence and, 5:1128
 of postoperative patient, 5:1156
 Plague vaccine, 5:887
 Plasma fluids, 5:620-621
 Plasma for shock, 4:265, 328, 1214, 1219
 Plasma-protein binding, 4:584
 Plasma thromboplastin antecedent (PTA) deficiency
 diagnosis of, 5:22-23
 surgical care in, 5:74

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
 Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
 Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1398 / Cumulative Index

- therapy for, 5:50
- Plasmapheresis in macroglobulinemia, 5:457-458
- Plastic surgery for burns, 4:1304-1312
- Platelets, disorders of, 5:27-30, 423-442
 - oral surgery in, 5:95-96
- Plumbism, 4:710-713, 718, 720, 723-725
- Plummer's disease (autonomous hyperfunctioning nodule), 6:508-509
- Pneumonia
 - acidosis from 5:653
 - rheumatic, 6:107
- Pneumonitis
 - from poisoning, 4:706-707
 - uremic, 6:107
- Poisoning
 - alkali, 4:729-733
 - antidotes for, 4:605, 616-624
 - barbiturate, 4:679-695
 - as cause of metabolic acidosis, 5:646
 - cosmetic, 4:643-646
 - disinfectant, 4:641-642
 - excretion in, 4:606-607
 - from household cleaning agents, 4:633-641, 731-733
 - insecticide, 4:626-632
 - iron, 4:671-677
 - lead, 4:710-728
 - mercury, 4:732-739
 - non-oral, 4:614-615
 - petroleum distillate, 4:697-708
 - salicylate, 4:648-669
 - from solvents, 4:642-643
 - treatment of
 - complications, 4:609-614
 - non-oral poisoning, 4:614-615
 - specific measures, 4:599-607
 - supportive, 4:607-609
- See also Toxic neuropathies
- Poliomyelitis, respiratory failure in, 6:33, 113
- Polyarteritis, drug-induced, 5:805
- Polycythemia
 - neuropathy with, 5:1267
 - vertigo and, 6:572, 575
- Polymyositis, drug-induced, 5:805
- Polyneuritis, 5:1211
 - bowel and bladder care in, 5:1214
 - diabetic, 5:1227-1228
 - respiratory failure in, 6:33
- See also Neuropathies
- Polyneuropathy, *see* Neuropathies
- Pompe's disease, 4:1002
- Porphyria, as metabolic neuropathy, 5:1231-1232
- Portal hypertension, 6:175-190
 - definition of, 6:175
 - in primary biliary cirrhosis, 6:211
- Postcholecystectomy syndrome, 5:531
- Posterior tibial neuropathy, 5:1224-1225
- Postinfarction syndrome, 4:178-179
- Postinfectious neuropathies, 5:1264-1265
 - respirator and airway care with, 5:1265
- Postmenopausal osteoporosis, *see* Osteoporosis—menopausal
- Postoperative pain
 - control of, 5:1088
 - in gynecologic patients, 5:1174-1177
 - nature of, 5:1174-1175
 - unpredictability, 5:1155-1156
 - oxymorphone for, 5:1142, 1176
 - treatment of, 5:1095, 1115, 1154-1163
 - regional-block therapy, 5:1183, 1185
- Postpartum pain
 - analgesics for, 5:1172-1174
 - control of, 5:1088
 - treatment of, 5:1095, 1115, 1118
- Postpericardiotomy syndrome, 4:170-176, 195
- Postural hypotension, vertigo and, 6:571-572, 574
- Potassium
 - basic considerations for, 5:663-664
 - deficiency of, 5:664-667
 - acidosis from, 5:653
 - alkalosis from, 5:657, 659, 665
 - excess of, 5:667-669
 - magnesium and, 5:663
 - wasting, management of, 4:518
- Pregnancy
 - defibrination syndromes in, 5:401-422
 - gallstones and, 5:488, 497
 - gonococcal arthritis in, 6:1133
 - hemorrhage in, 5:720-721
 - hydramnios in, 5:725
 - hydrops fetalis in, 5:725
 - hyperthyroidism in, 6:509-511, 513
 - immunizations in, 5:881
 - nausea and vomiting in, 5:714-715
 - pernicious vomiting, 5:1252
 - neuropathy with, 5:1220, 1223
 - oligohydramnios in, 5:724-725
 - surgery in, water and electrolyte disturbances from, 5:723-724
 - toxemia of, 5:716-720
 - water and electrolyte maintenance in, 5:715-716
- See also Abortion; Labor; Labor pain; Postpartum pain

- Premarital help by clergymen, 6:896-897
- Prematurity, mental retardation and, 4:754-756
- Primaquine, hemolytic anemia from, 5:794, 795
- Primary herpes with oral ulcers, 4:555-561
- Primidone
dosage and preparation of, 6:1228
epilepsy and, 6:1223
side-effects of, 6:1226-1227
- Progeria, 5:238
- Projective tests, 6:870-871
- Prostate, enlargement of, and renal failure, 6:933-934
- Prostheses, 5:903-905
definition of, 5:900-901
fitting of, 5:1050-1051
improvements in, 5:1055
for lower extremity amputations, 4:421-425, 427-439; *see also* Amputations
- Protein metabolic neuropathies, 5:1233-1234
- Protein therapy, for deficiency neuropathy, 5:1259
- "Prothrombin complex"
diagnosis of, 5:22-23
surgical care in, 5:75
therapy for, 5:50-51
- Pruritis
anaphylactic, 5:783, 784
antihistamines for, 5:811, 839-840
in drug allergy, 5:803, 811
in uremia, 6:1045
in urticaria, 5:825
- Pseudohermaphroditism, male, 5:201-202, 214-215
- Pseudohypothyroidism, 4:1010
- Pseudomonas aeruginosa
in burn wounds, 4:1256, 1257, 1259-1260, 1284
urinary tract infections with, 4:1164
- Pseudorettardation, 4:747, 749-762, 794-796, 801-818
associated with epilepsy, 4:801-818
non-neurologic, 4:749-762
speech disorders causing, 4:794-796
- Pseudoxanthoma elasticum, 5:33, 447
- Psoriatic arthritis, 5:1011, 1015
- Psychiatric disorders in uremia, 6:1014
- Psychiatric complications of epilepsy, 6:1247-1248
denial of illness, 6:1257-1258
groups of epileptic problem patients, emotional conditions, 6:1251-1253
family reactions, 6:1254-1255
hysteroepilepsy, 6:1251
iatrogenic illness, 6:1255, 1256-1260
mental deficiency, 6:1253
organic brain disease, 6:1253
seizure as problem, 6:1249-1251
status epilepticus, 6:1254-1255
neurosurgical indications, 6:1258
social reactions, 6:1255-1256
withdrawal seizures, 6:1256-1257
- Psychiatric patients, incidence of somatic complaints in, 6:652
- Psychiatric treatment
in atopic dermatitis, 5:875
in hereditary hemorrhagic disease, 5:111-124
in Huntington's disease, 5:340-342
of menopausal women, 5:554, 561, 587-595
in Parkinson's disease, 5:299
in urticaria, 5:830-831
- Psychologic examination of physically impaired persons, 5:896-897
stroke patients, 5:987-988
- Psychological disturbances in ill patients, 6:732-745, 866-869
- Psychologists, clinical, 6:866-884
function of, 6:869-871
- Psychometric tests, 6:870-871
- Psychosis
corticosteroids and, 5:850
differential diagnosis between neurosis and, 6:877-879
in the obese, 4:113-116
See also Schizophrenia
- Psychosomatic disorders, diagnosis of, 6:872-873, 879-881
- Psychotherapy
in alcoholism, 6:764-765, 768-772
for burned patient, 4:1291-1302
drugs in, 6:790-791, 793-805
family, 6:783-789, 806-807, 813-819

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1400 / Cumulative Index

- history taking as, 6:662-663
- in medical office, 6:777-792
- for mentally retarded, 4:778-779
- for obesity, 4:1121-1122, 1158-1159
- supervision of nonpsychiatric physician and, 6:842-856
- See also* Group therapy
- Psychotropic drugs, *see* Drugs—psychotropic
- Puberty in males, delayed onset of, 5:192-195
- Pulmonary complications in burn patients, 4:1264-1279
- Pulmonary infarction in shock, 4:309
- Pulmonary infiltrative disease, cor pulmonale and, 6:250
- Pulsus paradoxicus, 4:130-131
- Pupillogram, 6:1269-1271
- Purine-pyrimidine metabolism disorders, 4:1036-1037
- Purpura
 - anaphylactoid, 5:449-453, 803
 - as drug reaction, 5:1103
 - due to vascular lesions, 5:30-37
 - factitial, 5:460
 - fibrinolytic, 5:27, 384
 - Henoch-Schönlein's, 5:33-35, 449-453, 803, 853
 - hyperglobulinemia, 5:459
 - nonthrombocytopenic, 5:443-461
 - psychogenic, 5:459-460
 - pulmonary, 6:104
 - senile, 5:453-454
 - thrombocytopathic, 5:423-440
 - thrombocytopenic, 5:805
- Pyelography in renal failure, 6:1031
- Pyelonephritis, 6:925
 - diabetic nephropathy and, 4:40
 - management of, 5:630
 - potassium deficiency in, 5:666
 - pyloric stenosis, potassium depletion with, 5:665
 - treatment of, 4:519
- Pyoderma in diabetic, 4:76, 79
- Pyridoxine
 - dependency on, 4:1037-1038
 - for drug-induced neuropathy, 5:1237-1238, 1239
 - in oxaluria, 4:525, 526-527
- Pyruvic acid paste, 4:1305-1306
- Quinacrine and epilepsy, 6:1225
- Quinolines in treatment of dermatitis, 5:872, 877
- Rabies vaccine, 5:887
- Radial neuropathy, 5:1217-1218
- Radiation, lung damage from treatment of, 6:110
- Radiculitis with gout, 5:1230
- Radiculopathies, *see* Peripheral nerve syndromes
- Radioactive iodine uptake (RAIU), 6:444-447, 448
- Raynaud's disease
 - feet in, 4:357-358
 - hands in, 4:357-358
 - smoking with, 4:354, 367
 - supportive measures in, 4:367
 - with trophic changes, 4:367-368
 - local therapy, 4:267-268
 - vasodilator drugs, 4:378-380, 382
- Refraction, changes in, from diabetes, 4:62
- Refractory seizures, treatment of, 6:1229-1230
- Refsum's disease, 5:1211, 1232-1233
- Regional-block therapy, 5:1180-1196
 - for Bell's palsy, 5:1282-1283
 - development and current use of, 5:1180-1182
 - efficacy of, 5:1191-1193
 - implementation of, 5:1182-1184
 - for labor pain, 5:1168
 - for neuralgia, 5:1274
 - requirements for effective, 5:1194-1195
 - types available, 5:1184-1191
- Regression in acute illness, 6:732-736
- Rehabilitation
 - concept and scope of, 5:891-892
 - early mobilization in, 5:908
 - evaluation process in, 5:893-899
 - need for special centers for, 5:949-950, 970
- See also specific topics and organs*
- Reinforcers, positive, narcotics as, 5:1124
- Reiter's syndrome, 5:1011, 1015; 6:1140-1145, 1150, 1151
- Religion and care of patient, 6:885-889
- Renal colic, acute pain of, 5:1086, 1087, 1095
- Renal disease
 - acidosis in, 5:645-646
 - treatment, 5:651-652
 - dietary sodium in treatment of, 5:626-634
 - magnesium deficiency and, 5:671
 - magnesium excess and, 5:673
- See also specific renal disorders*
- Renal failure
 - after amphotericin B therapy, 4:953
 - chronic
 - complications, 4:40-41, 102

- diabetic neuropathy and, 4:35-40
 edema in, 4:38
 hypertension in, 4:37-38
 pericarditis and, 4:157-158
 protein balance in, 4:37
 serum albumin level in, 4:38-39
 water and electrolyte balance, 4:35-37
 in cirrhosis, 6:200-203
 diabetic nephropathy and, 4:32-34
 differential diagnosis of, 6:927-928
 nomenclature of, 6:927
 pathophysiology of, 6:934-935
 from poisoning, 4:609-610, 664, 737
 recovery after, 6:949-951
 treatment of, 6:923-924, 936-949
 dialysis, 6:946-949, 1054-1063
 diets, 6:924, 938-939, 1053-1054
See also Uremia
- Renal insufficiency, chronic, uremia and, 5:1231
- Renal stones, *see* Kidney stones
- Renal tubular acidosis, 5:646
 magnesium deficiency in, 5:671
 potassium depletion in, 5:666
 treatment of, 5:652
- Rendu-Osler-Weber disease, 5:33, 444-447
- Respiration
 in burn patients, 4:1263-1279
 irregularity of, in meningitis, 4:1175-1177
 mechanical aids to, 4:1175-1177
 in obese patients, 4:1162-1164
- Respirator care, *see* Airway and respirator care of neuropathic patient
- Respirators, *see* Ventilation—equipment for
- Respiratory acidosis, 5:653-655
- Respiratory alkalosis, 5:660-661
 in surgical patients, 5:711-713
- Respiratory depression, 6:31, 83
 antidotes to, 5:1149-1150, 1168
 labor and, 5:1167, 1168, 1171
 neuropathy and, 5:1244, 1253-1254
 postoperative, 5:1155-1159, 1175
 from potent analgesics, 5:1140, 1142, 1144, 1147, 1148
- Respiratory failure
 definition of, 6:33
 as emergency, 6:11
 obstructive
 aerosol therapy, 6:361-370
 cor pulmonale in, 6:248-260
 definition of, 6:12, 233
 hypoventilation and, 6:83
 management of secretions, 6:297-300, 353-354
 medications in, 6:346-360
 recognition of, 6:47
 respiratory acidosis and, 6:98
 tests for, 6:233-247
 therapy for infections, 6:322-324, 354
 tracheal intubation and tracheotomy in, 6:47-60
 restrictive, 6:26-46
 definition of, 6:12, 26, 103
 disorders producing, 6:32-42
 I.P.P.B. in, 6:102
 medication in, 6:103-117
 obstructive disease combined with, 6:238-239
 oxygen therapy in, 6:111-112
 pulmonary function in, 6:13, 27-32
 See also specific diseases
- Respiratory reactions in allergy, 5:783
 in drug allergy, 5:805
- Respiratory stimulants, 6:346-350
- Respiratory system
 functions of, 5:918-919
 impairment of, 5:919-921
 evaluation of those disabled, 5:921-923
 management, 5:924-927
 physical medicine techniques, 5:927-929
 normal mechanisms of, 6:15-16
 See also Lungs; Respiratory failure; Tuberculosis—pulmonary; Ventilation
- Rest pain in occlusive arterial disease, 4:113, 377, 387
- Retardation, mental
 amino acid metabolism disorders and, 4:1011, 1019-1029
 behavioral signs of, 4:791-794

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
 Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
 Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1402 / Cumulative Index

- beriberi and, 4:1038
- calcium metabolism disorders and, 4:1007-1011
- carbohydrate metabolism disorders and, 4:1039, 1042-1043
- cation-anion metabolic disorders and, 4:1039, 1042-1043
- chronic idiopathic hypoparathyroidism and, 4:1008-1010
- congenital lysing intolerance and, 4:1030-1031
- cretinism and, 4:1044-1046
- cystathioninuria and, 4:1034-1035
- differential diagnosis of, 4:773-775
- galactosemia and, 4:1003-1005
- gargoylism and, 4:1005-1006
- genetic, 4:837-851
- glycogen disease and, 4:1001-1003
- hereditary fructose intolerance and, 4:1003
- homocystinuria and, 4:1031
- hydroxykynureninuria and, 4:1034
- hyperglycemia and, 4:1029
- hypervolemia and, 4:1029-1030
- hypoglycemia and, 4:998-1001
- hypopituitarism and, 4:1046
- idiopathic infantile hypercalcemia and, 4:1007-1008
- irremedial organic, 4:748
- insulinoma and, 4:1001
- kwashiorkor and, 4:1036
- lipid metabolism, disorders and, 4:1011, 1012-1018
- maple syrup urine disease and, 4:1030
- mental institutions and, 4:834-836
- metabolic and endocrine causes of, 4:987-1047
- methionine malabsorption and, 4:1033
- misdiagnosis of, causes of, 4:750-753
- nephrogenic diabetes insipidus and, 4:1046
- oxidation-reduction metabolic disorder and, 4:1043-1044
- pellagra and, 4:1038
- pernicious anemia and, 4:1038-1039
- phenylketonuria and, 4:1031-1033
- pseudo, *see* Pseudoretardation
- psychologic, 4:747-748
- psychological evaluation of, 4:763-765
- purine-pyrimidine metabolism disorders and, 4:1036-1037
- pyridoxine dependency and, 4:1037-1038
- remedial, 4:747
 - as sequelae of meningitis, 4:983
- speech in, 4:787-791
- terminology for, 4:743-744
- tests for, 4:763-770, 793-794
- training programs for, 4:829-836
- treatment of, 4:745-747, 819-827, 987
- types of, 4:747-748
- tyrosinosis and, 4:1034
- urea cycle disorders and, 4:1035-1036
- vitamin metabolism disorders and, 4:1037-1039, 1040-1042
- Wilson's disease and, 4:1039, 1042
- Reticulocytosis of alcoholics, 5:1250
- Retina, detachment of, in diabetes, 4:70-72
- Retinopathy, diabetic, 4:63-70
 - pituitary suppression in, 4:64-65
 - by stalk section, 4:67-69
- Reye's syndrome, 4:1005
- Rheumatic disease, phenylpyrazole therapy for, 5:1107-1108
- Rheumatic fever
 - pancarditis of, 4:153-155
 - pericarditis of, 4:125, 153-155
 - in children, 4:193-194
 - penicillin therapy, 4:193
 - steroid therapy, 4:154, 193-194
- Rheumatoid arthritis
 - chronic pain of, 5:1086, 1088
 - median-nerve trauma and, 5:1220
 - neuropathy with, 5:1269-1270
 - with pericarditis, 4:156
 - in children, 4:194-195
 - pulmonary involvement in, 6:106, 112
 - rehabilitation in, 5:1011-1014, 1016-1019
 - side-effects of therapy for, 5:1101
- Rheumatoid spondylitis, 6:106
- Rhinitis, allergic
 - antihistamines for, 5:838, 839, 840-841, 842
 - corticosteroids for, 5:844
 - in food allergy, 5:853
- Rhinorrhea
 - as drug reaction, 5:1103
 - meningitis and, 4:978
- Rhizotomy to relieve pain, 5:1199-1200, 1205
- Riedel's struma, 6:492-495
- Ringer's lactate for burn therapy, 4:1222, 1224
- Rinne test, 6:593, 599
- Roentgenograms in epilepsy, 6:1195
- Roman Catholic patients, 6:894
- Rotch's sign in acute pericarditis, 4:128

- Rubella, arthritis with, 6:1148-1149, 1151
- Rubella vaccine, complications from, 5:886
- Ruptured intracranial saccular aneurysm
symptoms of, 5:974-975
See also Stroke patients
- Salicylamide therapy for pain, 5:1103-1104
- Salicylates
poisoning from, 4:648-649; 5:646, 652
in treatment of pain, 5:1096-1103
analgesic combinations, 5:1117-1118, 1129
side-effects, 5:1101-1103, 1104, 1118
- Sarcoidosis
cardiac involvement, 4:151
treatment of, 6:109-110
- Scapula, unstable, 5:1217
- Schistosomiasis of the liver, 6:160-163
- Schizophrenia
management of medical illness in, 6:695-703
obesity and, 4:1113-1116
progress of decompensation in, 6:700-701
psychotropic-drug hazards in, 6:795
sociopathy compared to, 6:709-710
- Schoenlein-Henoch's disease, 6:928
- Sciatic neuropathy, 5:1221-1222
- Scleroderma, pulmonary disturbances in, 6:105
- Sclerosis
amyotrophic lateral, 6:113
multiple, vertigo from, 6:579-585
- Scopolamine (1-hyoscine) for labor pain, 5:1166-1167, 1168-1169
- Scurvy, 5:31, 454-455
- Seborrhea in Parkinson's disease, 5:255, 275-276, 281
- Seborrheic dermatitis
with atopic dermatitis, 5:872, 877
differential diagnosis of, 5:866-867
- Sedation for labor pain, 5:1171
- Sedatives in treatment of pain, 5:1115, 1116, 1117, 1119
- side-effects of, 5:1118, 1136
- Seizures, 6:1179-1181
febrile convulsions, 6:1182-1189
major, 6:1217-1218, 1222-1224, 1228-1229
minor, 6:1218-1228
- Sensory deprivation and immobility, 6:649, 744
- Septic shock, 4:271, 321-344, 907-909
respiratory alkalosis in, 5:712-713
- Septicemia in meningococcal disease, 4:931
- Serum sickness-type reactions
allergic mechanisms in, 5:780
to drugs, 5:803-804, 811
to immunizations, 5:882
- Shock
acid-base correction in, 4:295
blood gases in, 4:296
cardiogenic, 4:299-318
clinical management of, 4:277-279, 282-293
hemorrhagic, 4:256-271, 274-276
oliguria and, 4:294, 296-297
peripheral vascular failure in, 4:288-289
plasma for, 4:265, 328, 1214, 1219
from poisoning, 4:610, 637, 675, 676
prevention of, 4:343
vasodilators in, 4:243-254, 295, 308-309, 312
vasopressors in, 4:243-254, 294-295, 306-308
volume expanders in, 4:293-294
See also Trauma; *specific types of shock*
- Short-acting block therapy, 5:1184-1185
- Shoulder dislocation, neuropathy from, 5:1216
- Shoulder rigidity in Parkinson's disease, 5:262, 279-280
- Silicosis, treatment of, 6:107-108
- Silo-filler's disease, 6:108
- Silver nitrate solution for burn infections, 4:1257-1258
- Silver sulfadiazine for burn infections, 4:1259-1261
- Sinusitis, treatment of pain of, 5:1117
- Skin, Graves' disease and, 6:529-531

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1404 / Cumulative Index

- Skin grafts in burn patients, 4:1307-1311
- Skin protection for neuropathic patient, 5:1213, 1232
- Skin rash from drugs, 5:1107, 1108
- Skin sensitivity, diminished with age, 5:1160
- Skin tests
 - for anaphylactic reactions, 5:789, 790
 - for drug allergy, 5:799-800, 808-809, 827
 - in food allergy, 5:828, 856-857
 - in immunizations, 5:885-888
 - for insect sting reactions, 5:818-820
- Smallpox vaccination
 - pregnancy and, 5:881
 - problems with, 5:876, 883-884
- Social work and medicine, 6:857-865
- Sociopathy
 - clergyman's role in, 6:890-891
 - definition of, 6:705-706
 - diagnosis of, 6:872-873, 881-884
 - recognition and management of, 6:704-710
- Sodium
 - deficiency of, in surgical patients, 5:708-709
 - dietary, in treatment of chronic renal disease, 5:626-634
 - potassium depletion and, 5:665
- Sodium bicarbonate in shock, 4:269
- Sodium iodide solution therapy for neuropathy, 5:1246-1247
- Sodium salicylate therapy for pain, 5:1099-1100, 1102
- Sodium sulfate therapy
 - for arsenic neuropathy, 5:1241
 - for lead neuropathy, 5:1242-1243
- Sodium thiosulphate solution therapy for neuropathy, 5:1246-1247
- Soft-tissue bleeding, 5:54, 88-90
- Spasmodic torticollis, surgical treatment of, 5:314-315
- Spastic, speech in, 4:797
- Special patients, 6:720-731
 - types of, 6:721
- Specificity theory of pain, 5:1083-1084
- Speech
 - causing pseudoretardation, 4:794-796
 - evaluation of, in disability, 5:898
 - mentally retarded and, 4:787-791
 - normal development of, 4:784-787
 - in Parkinson's disease, 5:276-277, 281
 - in spastic, 4:797
 - in specific diseases, 4:796-790
 - in stroke patients, 5:984-987
- Sphincter function, disturbance of by regional blocks, 5:1181
 - by surgery, 5:1199
- Spinal cord injuries, 5:949-970
 - bowel training in, 5:956-957
 - elective surgery in, 5:969
 - by level of damage (*table*), 5:951
 - need for rehabilitation center for, 5:949-950, 970
 - occupational therapy in, 5:960-962
 - phenol blocks in, 5:965-968
 - physical therapy in, 5:957-960
 - severe spasticity in, 5:965
 - sexual function in, 5:957, 968
 - skin care in, 5:954-955
 - urologic problems in, 5:955-956, 963-965, 968
- Spinal stress, *see* Low back pain
- Spinothalamic tractotomy to relieve pain, 5:1201
- Spirometry, 6:233-239
- Splenectomy in blood platelet disorders, 5:424
- Splenomegaly, thrombocytopenia with, 5:434-435
- Sporotrichosis, 6:1124-1126
- Sprue, nontropical and diabetes, 4:50
- Sputum examination, in post-burn patient, 4:1277
- Stapedectomy, vertigo after, 6:612
- Starling hypothesis, 4:1203, 1206
- Status asthmaticus, *see* Asthma—status asthmaticus
- Status epilepticus seizures, 6:1218
 - drugs effective against, 6:1228-1229
- Steatorrhea, magnesium loss in, 5:670
- Stereotaxic thalamotomy for relief of pain, 5:1206
- Steroid therapy
 - growth retardation and, 4:1000
 - in idiopathic chronic insulin resistance, 4:19-21
- for neuropathy
 - Bell's palsy, 5:1281
 - deficiency neuropathy, 5:1260
 - inflammatory neuropathy, 5:1264
 - vascular neuropathy, 5:1267, 1269-1270
- obesity from, 4:1126
- in pyogenic meningitis, 4:908
- in rheumatic pericarditis, 4:154, 193-194
- in shock, 4:269, 336
- topical, in necrobiosis lipoidica, 4:74
- in tuberculous pericarditis, 4:188
- See also* Corticosteroid therapy
- Stomach
 - occult bleeding of, 5:1102
 - pH of, effect of buffered aspirin on, 5:1098

- See also* Dyspepsia; Peptic ulcers
- Streptomycin therapy
 in neonatal meningitis, 4:912
 in tuberculous meningitis, 4:939-940
 in tuberculous pericarditis, 4:144
- Stroke patients
 basic physiological considerations in, 5:971-973
 body image in, 5:984
 defining location and etiology of lesion in, 5:973-978
 fractures in, 5:982-983
 frozen shoulder in, 5:983-989
 gauging functional loss in, 5:976-978
 incontinence in, 5:984
 physical rehabilitation of, 5:988-990
 psychologic evaluation in, 5:987-988
 spasticity in, 5:978-982
 speech defects in, 5:984-987
 vasomotor disturbances in, 5:983-984
 wheelchairs and other devices for, 5:990-993
- See also* Cerebrovascular diseases
- Struma lymphomatosa, *see* Hashimoto's thyroiditis
- Stuart-factor inhibitor, 5:379
- Subclavian steal syndrome, vertigo and, 6:571, 576
- Subdural effusion, 4:906-907, 936-937
 in bacterial meningitis, 4:907
 surgery for, 4:977-978
- Subdural taps in epilepsy, 6:1195, 1208
- Sulfamylon therapy for burn infections, 4:1255-1257, 1284
- Sulfobromophthalein retention and gallbladder nonvisualization, 5:501
- Surgical neuropathies, 5:1217, 1218-1219, 1222
- Sustained-release salicylate therapy for pain, 5:1098-1099, 1100
- Suture, cranial closure premature, 4:826-827
- Sweat, replacement of, in surgical patients, 5:704
- Sydenham's chorea
 diagnostic tests in, 5:355-357
 prognosis in, 5:358-359
 treatment of, 5:256, 351-360
- Sympathectomy
 lumbar, 4:403-404
 to relieve pain, 5:1199, 1204
- Sympathetic dystrophies, regional-block therapy for, 5:1184, 1185
- Syringomyelia, loss of sensation in, 5:1086
- Systemic allergic vasculitis, 4:147-160
- Systemic infection, treatment of pain of, 5:1095
- Systemic lupus erythematosus (SLE), Stuart-factor inhibitor in, 5:379
- Tamponade, cardiac, 4:129-130, 147, 157
- Telangiectasia, hereditary hemorrhagic, 5:444-447
- Testes, diseases of, affecting growth, 5:184-204
- Testicular androgen production diminished, 5:186-197
 increased, 5:197-200
- Testicular feminization, 5:201-202, 214-215
- Tetanus
 preventing recurrence of, 5:755
 stages of, 5:729-730
 treatment of, 5:730-756
 case histories, 5:741-753
 initial treatment, 5:731-733
 rehabilitation, 5:754-755
 of severe cases, 5:733-741
- Tetanus vaccine, complications from, 5:885
- Tetany
 acute attacks of, 4:1009-1010
 neonatal, 4:994-995
 in poisoning, 4:663
- Thalamic nucleus VPL for relief of pain, 5:1201-1202
- Thalidomide-induced neuropathy, 5:1239-1240
- Thallium neuropathy, 5:1246-1247
- Thiamine therapy for deficiency neuropathy, 5:1251-1255, 1260
- Thigh, effect of neuropathy on, 5:1223
- Thoracentesis in postpericardiotomy syndrome, 4:174

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.

Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.

Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1406 / Cumulative Index

- Thoracic anterolateral cordotomy to relieve pain, 5:1200
- Thoracoplasty, respiratory failure after, 6:37
- Thoracotomy, respiratory failure after, 6:36-37
- Thought disorders, diagnosis of, 6:872, 874-877
- Throat, pain in, surgical relief of, 5:1205
- Thromboangitis obliterans
anticoagulants in, 4:358-359
local care of extremities in, 4:354-357
neuropathy with, 5:1267
physical activity in, 4:351-353
smoking and, 4:353-354
with trophic changes, 4:361-365
- Thrombocythemia, 5:440-441
- Thrombocytopathia in uremia, 6:1038
- Thrombocytopenia, 5:27-29
from phenylpyrazoles, 5:1108
in uremia, 6:1038
- Thromboembolic disorders, complications from drug therapy in, 5:372-376
- Thrombophlebitis from dextropropoxyphene, 5:113
- Thrush in diabetic, 4:81
- Thyroid, diseases of, growth-affecting, 5:153-167
- Thyroid acropachy, 6:516
- Thyroid gland
diagnostic tests for diseases of, 6:441, 443-461
iodine organification in, 6:447-449
regulation of activity of, 6:450-453
thyroxine and triiodothyronine synthesis in, 6:443
- Thyroid hormones
in blood, 6:454-459
effects of, 6:460-461
- Thyroidectomy in hyperthyroidism, 6:497-499
with ophthalmopathy, 6:528
- Thyroiditis, 6:474-496
auto-immune, 6:484-492
classification of, 6:474
infectious, 6:474-475
subacute nonsuppurative, 6:475-484
- Thyrotoxicosis
Achilles tendon reflex in, 6:461
albumin catabolism in, 6:460
triiodothyronine suppression test in, 6:453
- Thyrotoxicosis factitia, 6:513
- Thyrotropic hormone (TSH), 6:450-453
- Tic douloureux, regional-block therapy for, 5:1184, 1185
- Tinea pedis in diabetic, 4:82-83
- Tineal's sign with neuropathy, 5:1220
- Tissue irritation from dextropropoxyphene, 5:1113
- Tissue pressure, pain from, 5:1174
- Tobacco-alcohol amblyopia, 5:1260-1261
- TOCP neuropathy, *see* Triorthocresyl phosphate neuropathy
- Tolazamide in maturity-onset diabetes in obese, 4:1187-1190
- Tolbutamide for maturity-onset diabetes in obese, 4:1187-1190
- Toothache, treatment of, 5:1095
- Torticollis, spasmodic, surgical treatment of, 5:314-315
- Toxemia of pregnancy, defibrination and, 5:420
- Toxic-complex type of reaction, fundamental mechanism of, 5:779
- Toxic neuropathies, treatment of
general scope, 5:1236-1237
varieties of neuropathies, 5:1240-1247
- Toxic synovitis of the hip, 6:114-115
- Tracheostomy, 4:1174-1175; 6:50-54, 72-73
- Tractotomy to relieve pain, 5:1200-1201
- Tranquilizers
for children, 4:777
in treatment of pain, 5:1115, 1116, 1117, 1119
labor pain, 5:1166
postoperative pain, 5:1162
side-effect, 5:1136
substituted for narcotics, 5:1129
See also Drugs—psychotropic
- Transfusion exchange, *see* Exchange transfusion
- Translocation in genetics, 4:838, 841, 842
- Transplantation, *see* Kidney—transplantation of
- Transplantation-rejection phenomena, 5:780
- Trauma
surgical, 5:1157
treatment of pain of, 5:1095
regional-block therapy, 5:1185
See also specific traumas
- Traumatic and compressive neuropathies, treatment of, 5:1215-1225, 1234
- Traumatic injury, acute pain of, 5:1086
- Tremor in Parkinson's disease, 5:260-273, 318

surgical relief of, 5:311-312
 Triceps skinfold thickness, measurement of, 4:1097-1098
 in children, 4:1155-1156
 table of standards for, 4:1098-1099
 Trigeminal nerve alcohol block, 5:1182, 1183-1184, 1274
 Trigeminal neuralgia, 5:1272-1274
 medical treatment of, 5:1272-1273
 surgical relief of, 5:1204-1205, 1273-1274
 Trigger point procaine block therapy, 5:1183, 1187
 Triglycerides and blood lipids, 6:1306-1309
 Trimethadione
 dosage and preparation of, 6:1228
 epilepsy and, 6:1225
 side-effects of, 6:1226-1227
 Triorthocresyl phosphate (TOCP) neuropathy, 5:1243-1245
 treatment of paralysis in, 5:1244
 Trisomy, genetic
 Klinefelter's syndrome, 4:842, 843, 847-848
 Turner's syndrome, 4:842, 843, 847-848; 5:219-226
 See also Down's syndrome
 Trunk rigidity in Parkinson's disease, 5:263-264
 Tuberculin skin test reaction, 5:780
 Tuberculosis
 as cause of meningitis, 4:947
 pulmonary, corticosteroids and, 5:850
 silicosis as predisposing to, 6:107-108
 Tuberculous arthritis, 6:1117-1123
 in children, 6:1113-1114
 Tumors
 adrenal, masculinizing, 5:175, 177-179
 affecting food control center, 4:1126, 1128
 brain, 4:946-947
 malignant, *see* Cancer; Malignant tumors
 ovarian, 5:209-214
 of pericardium, 4:209-212
 pseudo-, hemophilic, 5:90-91
 vertigo and, 6:576-579, 613

Turner's syndrome, 4:842, 843, 847-848; 5:219-226
 Typhus vaccine, 5:887
 Tyrosinosis, 4:1034
 Ulcers
 corneal, due to surgery, 5:1204
 of feet
 in arterial occlusion, 4:354-357, 361-367, 375-376
 in diabetes, 4:56-57, 75-76, 78, 111-118
 from prosthesis, 4:436
 in Raynaud's disease, 4:357-358, 367-368
 trophic, 5:1222, 1227, 1229
 gastrointestinal, in meningitis, 4:974
 intestinal, from mefenamic acid, 5:1109
 with necrobiosis lipodica, 4:74
 oral, acute, 4:558-559, 561, 563, 567-570
 peptic, *see* Peptic ulcers
 Ulnar neuropathy, 5:1218-1220
 Ultrasonic therapy, 5:910-911
 Ultrasound in pericardial effusion, 4:197-204
 Unilateral cordotomy to relieve pain, 5:1200-1201
 Upper extremity neuropathies, treatment of, 5:1215-1221
 Upper extremity rigidity in Parkinson's disease, 5:261-262, 280
 Upper root neuropathy, 5:1215-1216
 Urea-complexed salicylate therapy for pain, 5:1099
 Urea cycle disorders and mental retardation, 4:1035-1036
 Uremia
 acidosis and, 5:645-646
 bleeding in, 5:379-380
 hypocalcemia in, 5:678-680
 metabolic defects of, 6:924
 metabolic manifestations of, 6:1044-1050
 as metabolic neuropathy, 5:1231
 pericarditis with, 4:157-158
 treatment of chronic, 6:1036-1063
 use of drugs in, 6:1011-1035
 See also Azotemia

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
 Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
 Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.

1408 / Cumulative Index

- Urethral scarring, renal failure and, 6:933-934
- Urethritis, Reiter's syndrome with, 6:1140, 1142-1143
- Uric acid kidney stones, 4:470, 472-473, 531-536
- Urinalysis in epilepsy, 6:1208
- Urinary bleeding and fibrinolysis, 5:389-390
- Urinary tract, postoperative pain in, 5:1174
- Urine flow in shock, 4:296-297
- Urticaria, 5:825-836
 - anaphylactic, 5:783
 - in drug allergy, 5:802, 811, 826-827
 - as drug reaction, 5:1103, 1107, 1112
 - genesis of lesions of, 5:825-826
 - incidence of, 5:82
 - in insect sting reactions, 5:815
 - nonallergic, 5:775
 - treatment of, 5:826-835
 - antihistamines, 5:831-833, 834, 835, 838, 841
 - corticosteroids, 5:833, 844
- Uterus, "Couveliare," 5:409

- Vaccinations, *see* Immunizations
- Vaginal pain, postoperative, 5:1174, 1177
- Vaginal smear in regulation of hormone dosage, 5:554-558
- Vascular disease
 - menopause and, 5:581-586
 - pulmonary, cor pulmonale and, 6:250-251
- Vascular failure, peripheral, in shock, 4:288-289
- Vascular insufficiency
 - peripheral, treatment of pain of, 5:1095
 - vertigo from, 6:568-576, 611-612
- Vascular (ischemic) neuropathies, 5:1222-1223, 1266-1270
- Vasculitis
 - drug-induced, 5:805
 - vertigo and, 6:573
- Vasoconstriction, peripheral, intravenous injections and, 5:1157
- Vasodilation, reflex or indirect, in arterial occlusion, 4:363-365
- Vasodilator drugs
 - for arterial disorders in extremities, 4:370-382
 - for diabetes, 4:95-96, 115
 - for shock, 4:243-254, 295, 308-309, 312
- See also specific drugs*

- Vasomotor and vasotonic responses after long immobilization, 5:908
- Vasopressor drugs
 - for poisoning, 4:607-608, 610
 - for shock, 4:243-254, 294-295, 306-308
- See also specific drugs*
- Vasospastic diseases, *see specific diseases*
- Venous pressure, central, in shock, 4:280, 333-335
- Ventilation, 6:244-245
 - assisted, 6:81-91
 - definition of, 6:61, 81
 - indications for, 6:62, 83-85
 - I.P.P.B. in, 6:96-98, 311-312, 335-339
 - controlled, 6:61-80
 - definition of, 6:61-81
 - I.P.P.B. in, 6:311-317, 335, 341-342
 - emergency restoration of, 6:48
 - equipment for, 6:63-72, 90
 - classification for, 6:62
 - I.P.P.B., 6:92-96
- hyper-, *see* Respiratory alkalosis
- hypo-
 - aerosol therapy, 6:368
 - arterial pCO₂ and, 6:243-244
 - compensatory mechanisms in, 6:81-82
 - See also* Respiratory acidosis
 - perfusion abnormalities of, 6:240-243, 246
 - for poisoning, 4:686-687
 - in restrictive respiratory failure, 6:29-30
- Versenate therapy for toxic neuropathies, 5:1241, 1243
- Vertigo (dizziness)
 - benign paroxysmal positional, 6:606-607
 - definition of, 6:533-554
 - from epilepsy, 6:585-587
 - evaluation of, 6:594-604
 - after head injury, 6:587-590, 609-611
 - in Meniere's disease, 6:553, 555-557, 605-606
 - as metabolic problem, 6:612-613
 - in migraine, 6:591-593
 - from multiple sclerosis, 6:579-585
 - ocular causes of, 6:590-591
 - paroxysmal, 6:1275-1278
 - anatomy, 6:1278-1280
 - central nervous system, 6:1295-1296
 - history, 6:1280-1283

Cumulative Index / 1409

- labyrinth, 6:1293-1295
- middle ear, 6:1292-1293
- physical examination and tests, 6:1283-1292
- of peripheral and central origin, 6:613-614
- after stapedectomy, 6:612
- treatment of, 6:614-620
- from tumors, 6:576-579, 613
- from vascular insufficiency, 6:568-576, 611-612
- from vestibular neuronitis, 6:607-608
- vestibular-system criteria and, 6:604-605
- from whiplash injury, 6:608-609
- Vestibular neuronitis, vertigo from, 6:607-608
- V.I.P., syndrome, 6:721, 727-731
- Viral forms of arthritis, 6:1146-1153
- Visceral larva migrans, 6:157
- Visceral pain
 - perception of, 5:1085, 1199
 - surgical relief of, 5:1199, 1204
- Vision, loss of, in meningitis, 4:945, 980-981
- Visual disorganization, diagnosis of, 6:875
- Vitamin K
 - baseline requirement for, 5:701
 - deficiency of, 5:364-369
 - prolonged blood loss, 5:1103
- Vitamin metabolism disorders and mental retardation, 4:1037-1039, 1040-1041
- Vitamin therapy
 - for neuropathy
 - deficiency neuropathy, 5:1250-1259
 - diabetic polyneuritis, 5:1228
 - drug-induced neuropathy, 5:1237-1238, 1239
 - metabolic neuropathy, 5:1235
 - TOCP neuropathy, 5:1244
- Vitamins
 - baseline requirement for, 5:701
 - in renal failure, 6:1029
- Vocational evaluation in disability, 5:898-899
- in cardiac disability, 5:936-937
- in degenerative neurologic disease, 5:1007-1008
- in peripheral nerve syndromes, 5:1002
- in respiratory disabilities, 5:923
- in spinal cord injuries, 5:962
- Voice, parkinsonian, 5:276-277, 281
- Volume expanders for shock, 4:293-294
- Von Economo's disease, 5:284
- Von Gierke's disease, 4:1001-1002
- Von Willebrand's disease
 - diagnosis of, 5:23-24
 - surgical care in, 5:70-72
 - therapy for, 5:52-53
- Vulvovaginitis, 4:81
- Waldenström's macroglobulinemia, vertigo and, 6:572-573
- Wallenberg syndrome, vertigo in, 6:569-570
- Water
 - body, *see* Body water
 - "hard," 5:673
- Water intoxication
 - in obstetric patients, 5:724
 - in surgical patients, 5:708
- Waterhouse-Friderichsen syndrome, meningococcal meningitis and, 4:936
- Weber test, 6:598-599
- Wegener's granuloma, 6:106, 251
- Weight loss for treatment of cardiopulmonary disturbances of obesity, 4:1168-1171
- Wernicke-Korsakoff syndrome with deficiency neuropathy, 5:1251, 1254
- Wilson's disease, 5:256, 274
 - prognosis in, 5:328-329
 - treatment of, 5:321-331
- Wintergreen oil, *see* Salicylates
- Wryneck, regional-block therapy for, 5:1183
- Xanthine kidney stones, 4:471, 536-537
- Xanthinuria, 4:536-537
- Xanthoma, eruptive, 4:82
- Yellow fever vaccine, 5:887

Volume 4, pages 1-232, January issue; pages 233-451, March; pages 452-586, May; pages 587-868, July; pages 869-1070, September; pages 1071-1374, November.
 Volume 5, pages 1-243, January issue; pages 244-468, March; pages 469-604, May; pages 605-766, July; pages 767-1070, September; pages 1071-1342, November.
 Volume 6, pages 1-218, January issue; pages 219-430, March; pages 431-630, May; pages 631-910, July; pages 911-1168, September; pages 1169-1410, November.